US20220249976A1 - Continuous crystallization of cannabinoids in a stirred-tank reactor - Google Patents
Continuous crystallization of cannabinoids in a stirred-tank reactor Download PDFInfo
- Publication number
- US20220249976A1 US20220249976A1 US17/628,853 US202017628853A US2022249976A1 US 20220249976 A1 US20220249976 A1 US 20220249976A1 US 202017628853 A US202017628853 A US 202017628853A US 2022249976 A1 US2022249976 A1 US 2022249976A1
- Authority
- US
- United States
- Prior art keywords
- cannabinoid
- rich solution
- cstr
- solution
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 419
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 418
- 238000002425 crystallisation Methods 0.000 title description 36
- 230000008025 crystallization Effects 0.000 title description 31
- 229940065144 cannabinoids Drugs 0.000 title description 26
- 238000002156 mixing Methods 0.000 claims abstract description 83
- 239000002245 particle Substances 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 66
- 230000001939 inductive effect Effects 0.000 claims abstract description 20
- 238000007599 discharging Methods 0.000 claims abstract description 10
- 239000013078 crystal Substances 0.000 claims description 57
- 239000002904 solvent Substances 0.000 claims description 56
- 239000012530 fluid Substances 0.000 claims description 48
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 27
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 27
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 23
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 claims description 20
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 19
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 19
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 17
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 14
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 claims description 13
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 claims description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 12
- OIVPAQDCMDYIIL-UHFFFAOYSA-N 5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-7-propylchromene-6-carboxylic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCC)C(C(O)=O)=C2O OIVPAQDCMDYIIL-UHFFFAOYSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 12
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 10
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- -1 Δ8-THCV Chemical compound 0.000 claims description 10
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 claims description 9
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 9
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims description 9
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 9
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 8
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims description 8
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 claims description 8
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 8
- CZXWOKHVLNYAHI-LSDHHAIUSA-N 2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid Chemical compound OC1=C(C(O)=O)C(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 CZXWOKHVLNYAHI-LSDHHAIUSA-N 0.000 claims description 7
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 claims description 7
- FAVCTJGKHFHFHJ-GXDHUFHOSA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-propylbenzoic acid Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-GXDHUFHOSA-N 0.000 claims description 7
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 claims description 7
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 claims description 7
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 claims description 7
- IXJXRDCCQRZSDV-GCKMJXCFSA-N (6ar,9r,10as)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6h-1,9-epoxybenzo[c]chromene Chemical compound C1C[C@@H](C(O2)(C)C)[C@@H]3C[C@]1(C)OC1=C3C2=CC(CCCCC)=C1 IXJXRDCCQRZSDV-GCKMJXCFSA-N 0.000 claims description 6
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000021715 photosynthesis, light harvesting Effects 0.000 claims description 6
- OMHYGQBGFWWXJK-UHFFFAOYSA-N cyclobutane-1,2,3,4-tetracarboxylic acid;dihydrate Chemical compound O.O.OC(=O)C1C(C(O)=O)C(C(O)=O)C1C(O)=O OMHYGQBGFWWXJK-UHFFFAOYSA-N 0.000 claims description 5
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 5
- 239000001294 propane Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 4
- 239000001273 butane Substances 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 4
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940090181 propyl acetate Drugs 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- CZXWOKHVLNYAHI-UHFFFAOYSA-N CBDVA Natural products OC1=C(C(O)=O)C(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 CZXWOKHVLNYAHI-UHFFFAOYSA-N 0.000 claims 2
- FAVCTJGKHFHFHJ-UHFFFAOYSA-N CBGVA Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-UHFFFAOYSA-N 0.000 claims 2
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 2
- 241000223184 Cucumber Bulgarian virus Species 0.000 claims 2
- IQSYWEWTWDEVNO-UHFFFAOYSA-N THCVA Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCC)C(C(O)=O)=C2O IQSYWEWTWDEVNO-UHFFFAOYSA-N 0.000 claims 2
- WVOLTBSCXRRQFR-DLBZAZTESA-M cannabidiolate Chemical compound OC1=C(C([O-])=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-M 0.000 claims 2
- 239000000243 solution Substances 0.000 description 210
- 229960004242 dronabinol Drugs 0.000 description 33
- 238000010899 nucleation Methods 0.000 description 21
- 230000006911 nucleation Effects 0.000 description 21
- 229950011318 cannabidiol Drugs 0.000 description 18
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 238000009826 distribution Methods 0.000 description 12
- ZLYNXDIDWUWASO-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7h-benzo[c]chromene-1,9,10-triol Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)(O)C2O ZLYNXDIDWUWASO-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 8
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 8
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 6
- IGHTZQUIFGUJTG-UHFFFAOYSA-N cannabicyclol Chemical compound O1C2=CC(CCCCC)=CC(O)=C2C2C(C)(C)C3C2C1(C)CC3 IGHTZQUIFGUJTG-UHFFFAOYSA-N 0.000 description 6
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 6
- 229960003453 cannabinol Drugs 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 5
- 0 *C([3H])[V].*C[3H].C.C.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)CC21.CCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)CC21.[3H]C.[3H]C[V].[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCC)c(C(=O)O)c(O)c12.[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCC)cc(O)c12.[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCCCC)c(C(=O)O)c(O)c12.[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCCCC)cc(O)c12 Chemical compound *C([3H])[V].*C[3H].C.C.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)CC21.CCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)CC21.[3H]C.[3H]C[V].[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCC)c(C(=O)O)c(O)c12.[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCC)cc(O)c12.[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCCCC)c(C(=O)O)c(O)c12.[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCCCC)cc(O)c12 0.000 description 5
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 5
- 229930191614 cannabinolic acid Natural products 0.000 description 5
- JVOHLEIRDMVLHS-UHFFFAOYSA-N ctk8i6127 Chemical compound C1=2C(O)=C(C(O)=O)C(CCCCC)=CC=2OC2(C)CCC3C(C)(C)C1C23 JVOHLEIRDMVLHS-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 240000004308 marijuana Species 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- YKKHSYLGQXKVMO-HZPDHXFCSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)C=C(C)C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O YKKHSYLGQXKVMO-HZPDHXFCSA-N 0.000 description 4
- YCBKSSAWEUDACY-IAGOWNOFSA-N 11-hydroxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(CO)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YCBKSSAWEUDACY-IAGOWNOFSA-N 0.000 description 4
- NAGBBYZBIQVPIQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-prop-1-en-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)=C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C NAGBBYZBIQVPIQ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 description 4
- QHCQSGYWGBDSIY-HZPDHXFCSA-N tetrahydrocannabinol-c4 Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCC)=CC(O)=C3[C@@H]21 QHCQSGYWGBDSIY-HZPDHXFCSA-N 0.000 description 4
- YOVRGSHRZRJTLZ-HZPDHXFCSA-N 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(C(O)=O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YOVRGSHRZRJTLZ-HZPDHXFCSA-N 0.000 description 3
- YOVRGSHRZRJTLZ-UHFFFAOYSA-N Delta9-THCA Natural products C1=C(C(O)=O)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 YOVRGSHRZRJTLZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OQCOBNKTUMOOHJ-RSGMMRJUSA-N (5as,6s,9r,9ar)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-2-carboxylic acid Chemical compound C1=2C(O)=C(C(O)=O)C(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O OQCOBNKTUMOOHJ-RSGMMRJUSA-N 0.000 description 2
- HJMCQDCJBFTRPX-RSGMMRJUSA-N (5as,6s,9r,9ar)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-4-carboxylic acid Chemical compound [C@H]1([C@@H](CC[C@@]2(O)C)C(C)=C)[C@@H]2Oc2c(C(O)=O)c(CCCCC)cc(O)c21 HJMCQDCJBFTRPX-RSGMMRJUSA-N 0.000 description 2
- WIDIPARNVYRVNW-CHWSQXEVSA-N (6ar,10ar)-3,6,6,9-tetramethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound CC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1 WIDIPARNVYRVNW-CHWSQXEVSA-N 0.000 description 2
- TZGCTXUTNDNTTE-DYZHCLJRSA-N (6ar,9s,10s,10ar)-6,6,9-trimethyl-3-pentyl-7,8,10,10a-tetrahydro-6ah-benzo[c]chromene-1,9,10-triol Chemical compound O[C@@H]1[C@@](C)(O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 TZGCTXUTNDNTTE-DYZHCLJRSA-N 0.000 description 2
- CYQFCXCEBYINGO-SJORKVTESA-N (6as,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-SJORKVTESA-N 0.000 description 2
- YEDIZIGYIMTZKP-UHFFFAOYSA-N 1-methoxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene Chemical compound C1=C(C)C=C2C3=C(OC)C=C(CCCCC)C=C3OC(C)(C)C2=C1 YEDIZIGYIMTZKP-UHFFFAOYSA-N 0.000 description 2
- XWIWWMIPMYDFOV-UHFFFAOYSA-N 3,6,6,9-tetramethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2OC(C)(C)C3=CC=C(C)C=C3C2=C1O XWIWWMIPMYDFOV-UHFFFAOYSA-N 0.000 description 2
- VAFRUJRAAHLCFZ-GHRIWEEISA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2-hydroxy-4-methoxy-6-pentylbenzoic acid Chemical compound CCCCCC1=CC(OC)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O VAFRUJRAAHLCFZ-GHRIWEEISA-N 0.000 description 2
- GGVVJZIANMUEJO-UHFFFAOYSA-N 3-butyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCC)C=C3OC(C)(C)C2=C1 GGVVJZIANMUEJO-UHFFFAOYSA-N 0.000 description 2
- IPGGELGANIXRSX-RBUKOAKNSA-N 3-methoxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenol Chemical compound COC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-RBUKOAKNSA-N 0.000 description 2
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 description 2
- GKVOVXWEBSQJPA-UONOGXRCSA-N 5-methyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound CC(=C)[C@@H]1CCC(C)=C[C@H]1C1=C(O)C=C(C)C=C1O GKVOVXWEBSQJPA-UONOGXRCSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IPGGELGANIXRSX-UHFFFAOYSA-N Cannabidiol monomethyl ether Natural products COC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-UHFFFAOYSA-N 0.000 description 2
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- NHZMSIOYBVIOAF-UHFFFAOYSA-N cannabichromanone A Natural products O=C1C(CCC(C)=O)C(C)(C)OC2=CC(CCCCC)=CC(O)=C21 NHZMSIOYBVIOAF-UHFFFAOYSA-N 0.000 description 2
- VAFRUJRAAHLCFZ-UHFFFAOYSA-N cannabigerolic acid monomethyl ether Natural products CCCCCC1=CC(OC)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O VAFRUJRAAHLCFZ-UHFFFAOYSA-N 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- BBRMJCAPNGJKEM-AQASXUMVSA-N (2E,4E)-N-isobutyl-2,4-dodecadienamide Chemical compound CCCCCCC\C=C\C=C\C(=O)NCC(C)C BBRMJCAPNGJKEM-AQASXUMVSA-N 0.000 description 1
- VLGRWXYRKYWRPX-VSRLVKTQSA-N (2e,4e,8z,10z)-n-(2-methylpropyl)dodeca-2,4,8,10-tetraenamide Chemical compound C\C=C/C=C\CC\C=C\C=C\C(=O)NCC(C)C VLGRWXYRKYWRPX-VSRLVKTQSA-N 0.000 description 1
- COURSARJQZMTEZ-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-propylbenzene-1,3-diol Chemical compound OC1=CC(CCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C COURSARJQZMTEZ-UHFFFAOYSA-N 0.000 description 1
- ZTGXAWYVTLUPDT-ZWKOTPCHSA-N 2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-3-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-ZWKOTPCHSA-N 0.000 description 1
- YCBKSSAWEUDACY-UHFFFAOYSA-N 7-Hydroxy-Delta1-THC Natural products C1=C(CO)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 YCBKSSAWEUDACY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- BBRMJCAPNGJKEM-UHFFFAOYSA-N Alk12 Natural products CCCCCCCC=CC=CC(=O)NCC(C)C BBRMJCAPNGJKEM-UHFFFAOYSA-N 0.000 description 1
- VLGRWXYRKYWRPX-UHFFFAOYSA-N Alk8E Natural products CC=CC=CCCC=CC=CC(=O)NCC(C)C VLGRWXYRKYWRPX-UHFFFAOYSA-N 0.000 description 1
- QQZAXBDNLUDOMH-IXKICFERSA-N CCCCCc1cc(O)c2c(c1)OC(C)(C)C1=C2C(O)C(C)(O)CC1.[H][C@@]12CC[C@@H](C)C=C1c1c(O)cc(CCCCC)cc1OC2(C)C.[H][C@@]12CC[C@H](C)C=C1c1c(O)cc(CCCCC)cc1OC2(C)C.[H][C@]12Oc3c(C(=O)O)c(CCC)cc(O)c3[C@@]1([H])[C@]([H])(C(=C)C)CC[C@]2(C)O.[H][C@]12Oc3c(C(=O)O)c(CCCCC)cc(O)c3[C@@]1([H])[C@]([H])(C(=C)C)CC[C@]2(C)O.[H][C@]12Oc3cc(CCC)cc(O)c3[C@@]1([H])[C@]([H])(C(=C)C)CC[C@]2(C)O Chemical compound CCCCCc1cc(O)c2c(c1)OC(C)(C)C1=C2C(O)C(C)(O)CC1.[H][C@@]12CC[C@@H](C)C=C1c1c(O)cc(CCCCC)cc1OC2(C)C.[H][C@@]12CC[C@H](C)C=C1c1c(O)cc(CCCCC)cc1OC2(C)C.[H][C@]12Oc3c(C(=O)O)c(CCC)cc(O)c3[C@@]1([H])[C@]([H])(C(=C)C)CC[C@]2(C)O.[H][C@]12Oc3c(C(=O)O)c(CCCCC)cc(O)c3[C@@]1([H])[C@]([H])(C(=C)C)CC[C@]2(C)O.[H][C@]12Oc3cc(CCC)cc(O)c3[C@@]1([H])[C@]([H])(C(=C)C)CC[C@]2(C)O QQZAXBDNLUDOMH-IXKICFERSA-N 0.000 description 1
- IXJXRDCCQRZSDV-UHFFFAOYSA-N CCCCCc1cc2c3c(c1)OC(C)(C)C1CCC(C)(CC31)O2 Chemical compound CCCCCc1cc2c3c(c1)OC(C)(C)C1CCC(C)(CC31)O2 IXJXRDCCQRZSDV-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
- 241000288748 Chrysochloridae Species 0.000 description 1
- SBPMGFIOIRMBJJ-UHFFFAOYSA-N Delta7-cis-iso-tetrahydrocannabivarin Natural products C1C2(C)CCC(C(C)=C)C1C1=C(O)C=C(CCC)C=C1O2 SBPMGFIOIRMBJJ-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 description 1
- XLHIYUYCSMZCCC-VMPITWQZSA-N Yangonin Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC(OC)=CC(=O)O1 XLHIYUYCSMZCCC-VMPITWQZSA-N 0.000 description 1
- AYXCIWVJOBQVFH-ZDUSSCGKSA-N Yangonin Natural products COC1=CC(=O)O[C@H](C1)C=Cc2ccc(OC)cc2 AYXCIWVJOBQVFH-ZDUSSCGKSA-N 0.000 description 1
- RRQVSLLVCGRJNI-UHFFFAOYSA-N ac1l4h72 Chemical compound C1C2(C)CCC(C(C)(C)O)C1C1=C(O)C=C(CCC)C=C1O2 RRQVSLLVCGRJNI-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- ORIYPICUSOGUOA-UHFFFAOYSA-N cannabidiol propyl analogue Natural products CCCc1cc(O)c(C2CC(=CCC2C(=C)C)C)c(O)c1 ORIYPICUSOGUOA-UHFFFAOYSA-N 0.000 description 1
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010964 desupersaturation Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000012165 plant wax Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000956 solid--liquid extraction Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- SBPMGFIOIRMBJJ-CTHAPGQVSA-N δ-7-cis-isotetrahydrocannabivarin Chemical compound C1[C@@]2(C)CC[C@@H](C(C)=C)C1C1=C(O)C=C(CCC)C=C1O2 SBPMGFIOIRMBJJ-CTHAPGQVSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0036—Crystallisation on to a bed of product crystals; Seeding
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0053—Details of the reactor
- B01J19/006—Baffles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0203—Solvent extraction of solids with a supercritical fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0063—Control or regulation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0053—Details of the reactor
- B01J19/0066—Stirrers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/18—Stationary reactors having moving elements inside
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J4/00—Feed or outlet devices; Feed or outlet control devices
- B01J4/001—Feed or outlet devices as such, e.g. feeding tubes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0004—Crystallisation cooling by heat exchange
- B01D9/0009—Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0018—Evaporation of components of the mixture to be separated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
- B01D9/0054—Use of anti-solvent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2204/00—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices
- B01J2204/002—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices the feeding side being of particular interest
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2204/00—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices
- B01J2204/005—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices the outlet side being of particular interest
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00049—Controlling or regulating processes
- B01J2219/00051—Controlling the temperature
- B01J2219/00074—Controlling the temperature by indirect heating or cooling employing heat exchange fluids
- B01J2219/00087—Controlling the temperature by indirect heating or cooling employing heat exchange fluids with heat exchange elements outside the reactor
- B01J2219/00094—Jackets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00761—Details of the reactor
- B01J2219/00763—Baffles
- B01J2219/00765—Baffles attached to the reactor wall
- B01J2219/00768—Baffles attached to the reactor wall vertical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present disclosure generally relates to methods of crystallizing cannabinoids.
- the present disclosure relates to continuous-mode cannabinoid-crystallization methods as opposed to batch-mode cannabinoid-crystallization methods.
- Cannabinoids are often defined in pharmacological terms as a class of compounds that exceed threshold-binding affinities for specific receptors found in central-nervous-system tissues and/or peripheral tissues.
- the interactions between cannabinoids and their receptors are under active investigation by a number of researchers, because the resultant effects are demonstrably important both in medicinal and reactional contexts.
- Many medicinal and recreational cannabinoid products feature cannabinoids in crystalline form. Methods for producing such products typically rely on batch-mode crystallization protocols. Unfortunately, batch-mode crystallization protocols are difficult to control—especially at large scale—and they are often associated with inconsistent product specifications (such as crystal-size distribution, polymorphic form, and/or crystal morphology). Such inconsistent product specifications may negatively impact downstream processes and/or consumer experiences in both medicinal and recreational contexts.
- Continuous-crystallization methods are associated with efficient use of solvents, energy, and space, and they are associated with minimal waste production.
- Continuous stirred-tank reactors are a type of reactor that can be configured to operate in a manner that is suitable for inducing crystallization in a continuous-mode process.
- Continuous-crystallization methods may be designed towards providing near plug-flow conditions (i.e. conditions under which a fluid flows with minimal shearing between adjacent layers) by operating multiple CSTRs in series.
- CSTRs typically feature an impeller and baffles to provide turbulent agitation to fluid within the CSTR.
- Fluid turbulence in a CSTR is associated with continuous generation of swirling eddy currents due to fluid-impeller and/or fluid-baffle interactions.
- the fluid mechanics associated with such conditions are highly complex in that there are a number of confounding variables contributing to turbulent mixing conditions (e.g. impeller geometry, impeller speed, impeller location within the CSTR, baffle spacing, baffle geometry, baffle orientation, fluid viscosity, etc.).
- the methods of the present disclosure utilize continuous stirred-tank reactors (CSTRs) that are configured for continuous flow under carefully controlled conditions.
- CSTRs continuous stirred-tank reactors
- the methods of the present disclosure provide access to a plurality of crystalline cannabinoid materials.
- the methods of the present disclosure provide access to crystalline-cannabinoid materials with narrow size distributions, and/or narrow polymorphic distributions.
- the present disclosure posits that these features are engendered by the utilization of turbulent mixing conditions in a CSTR.
- the present disclosure relates to a method for producing crystalline cannabinoid particles in continuous mode, the method comprising: preparing a cannabinoid-rich solution that comprises a first cannabinoid; inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid; flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner; mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR; discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the CSTR; and separating crystalline cannabinoid particles from the plurality of crystalline can
- the critical Reynolds is about equal to a Reynolds number above which a power number for the reactor is about constant. In select embodiments of the present disclosure, the critical Reynolds number is greater than 10,000.
- the CSTR has a capacity between about 30 cc and about 400 L.
- mixing the cannabinoid-rich solution under turbulent mixing conditions includes mixing the cannabinoid-rich solution with a Rushton turbine, a propeller, an anchor impeller, a gate-anchor impeller, a paddle impeller, a helical-screw impeller, a helical-ribbon impeller, or a combination thereof.
- the CSTR comprises a baffle that is shaped, oriented, or positioned to redirect flow within the CSTR.
- the baffle is one of a plurality of baffles.
- the CSTR is cylindrical
- the impeller is positioned and oriented to align the axis of rotation of the impeller with the cylinder axis.
- turbulently mixing the cannabinoid-rich solution with the mixer comprises turbulently mixing the cannabinoid-rich solution with the mixer wherein the impeller diameter is about one-third the diameter of the CSTR.
- the methods of the present disclosure further comprise cooling the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR.
- the first cannabinoid is THC ( ⁇ 9-THC), THCA, ⁇ 8-THC, trans- ⁇ 10-THC, cis ⁇ 10-THC, THCV, THCVA, ⁇ 8-THCV, ⁇ 9-THCV, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA CBL, CBLA, CBLV, CBLVA, CBT, CBTA, or cannabicitran.
- the cannabinoid-rich solution comprises a cannabinoid extract, a cannabinoid resin, a cannabinoid distillate, a cannabinoid isolate, or a combination thereof.
- the cannabinoid-rich solution comprises THC ( ⁇ 9-THC), THCA, ⁇ 8-THC, trans- ⁇ 10-THC, cis ⁇ 10-THC, THCV, THCVA, ⁇ 8-THCV, ⁇ 9-THCV, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA CBL, CBLA, CBLV, CBLVA, CBT, CBTA, cannabicitran, or a combination thereof.
- the cannabinoid-rich solution comprises a solvent.
- the solvent may comprise pentane, hexane, heptane, methanol, ethanol, isopropanol, dimethyl sulfoxide, acetone, ethyl acetate, diethyl ether, tert-butyl methyl ether, water, acetic acid, anisole, 1-butanol, 2-butanol, butane, butyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, propane, propyl acetate, trimethylamine, or a combination thereof.
- the cannabinoid-rich solution has a viscosity of between about 0.05 cP and about 250 cP at an inlet to the CSTR.
- the cannabinoid-rich solution has a fluid density of between about 0.2 g/mL and about 1,700 g/mL at an inlet to the CSTR.
- the cannabinoid-rich solution has a temperature of between about 0° C. and about 50° C. at an inlet to the CSTR.
- the inducing of the cannabinoid-rich solution to the supersaturated state precedes the flowing of the cannabinoid-rich solution through the CSTR.
- the inducing of the cannabinoid-rich solution to the supersaturated state is concurrent the mixing of the cannabinoid-rich solution.
- the cannabinoid-rich solution further comprises an excipient.
- the methods of the present disclosure further comprise dispersing a plurality of seed crystals into the cannabinoid-rich solution concurrent with the mixing of the cannabinoid-rich solution.
- the methods of the present disclosure further comprise flowing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution into an additional CSTR, mixing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution to form a plurality of larger crystalline cannabinoid particles within the additional CSTR, and discharging the plurality of larger crystalline cannabinoid particles and the cannabinoid-depleted solution from the additional CSTR in a continuous manner to provide a flow rate through the CSTR.
- Separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may include separating the larger crystalline cannabinoid particles from plurality of crystalline cannabinoid particles and/or the cannabinoid-depleted solution.
- mixing the cannabinoid-rich solution under turbulent mixing conditions includes mixing the cannabinoid-rich solution with an energy dissipation rate to produce eddies with a Kolmogorov length scale larger than the size of the crystalline cannabinoid particles.
- inducing the cannabinoid-rich solution to a supersaturated state includes evaporating at least a portion of the cannabinoid-rich solution.
- FIG. 1 shows schematic diagram of an exemplary continuous stirred-tank reactor, which may be employed in executing a method in accordance with the present disclosure.
- FIG. 2 shows a schematic diagram of two exemplary continuous stirred-tank reactors linked in series, which may be employed in executing a method in accordance with the present disclosure.
- FIG. 3 shows a method for continuously preparing crystalline cannabinoid particles in accordance with the present disclosure.
- the methods of the present disclosure leverage the combination of such kinetically unstable solutions with turbulent mixing conditions to induce crystal nucleation and/or growth under controlled, repeatable conditions.
- the result is a series of methods that provide crystalline cannabinoid materials with narrow crystal-size distributions and consistent polymorphic character.
- Such crystalline cannabinoids are likely to be useful in both medical and recreational contexts.
- the present disclosure relates to a method for producing crystalline cannabinoid particles in continuous mode, the method comprising: preparing a cannabinoid-rich solution that comprises a first cannabinoid; inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid; flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner; mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR; discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the CSTR; and separating crystalline cannabinoid particles from the plurality of crystalline can
- inducing a cannabinoid-rich solution into a supersaturated state primes the solution for cannabinoid crystallization.
- Such inducing may be driven by a variety of factors such as temperature decrease, pH adjustment, solute addition, solvent evaporation, co-solvent addition, non-solvent addition, or a combination thereof.
- the particular cannabinoid-rich solution may be characterized by a saturation curve (i.e. a plot of saturation concentration as a function of temperature for a particular pressure) which delineates a boundary between undersaturation and supersaturation conditions.
- a saturation curve i.e. a plot of saturation concentration as a function of temperature for a particular pressure
- the cannabinoid-rich solution becomes supersaturated, such that the supersaturated solution is in a metastable state, wherein a suitable initiation event will induce nucleation and crystal growth.
- Cannabinoid solubility studies indicate that inducing the cannabinoid-rich solution to a supersaturated state in which the particular cannabinoid has a supersaturated concentration that is greater than its corresponding saturation concentration provides sufficient supersaturation for turbulent-flow-induced nucleation and/or growth in a continuous fashion provided the turbulent-flow-related parameters meet particular conditions.
- turbulent mixing conditions within a CSTR may be quantified by the Reynolds number (Re) as defined as by EQN. 1.
- N i is the rotation rate of the CSTR impeller (in s ⁇ 1 );
- D i is the diameter of the CSTR impeller (in m);
- ⁇ is the fluid density (in kg/m 3 );
- ⁇ is the fluid viscosity (kg/m ⁇ s).
- the Reynolds number describes the intensity of mixing within a CSTR equipped with a single impeller.
- the severity of the turbulent flow conditions required to induce crystal nucleation/growth from a particular cannabinoid-rich solution will vary depending on the particulars of the cannabinoid rich solution and the extent of supersaturation. However, for any particular solution/CSTR combination, there is a critical Reynolds number that defines the minimum conditions required to ensure turbulent mixing.
- turbulent mixing conditions within a CSTR may be further quantified by the Power Number (N p ) as defined as by EQN. 2.
- N p P ⁇ ⁇ N i 3 ⁇ D i 5 EQN . ⁇ 2
- P is the input power (in kg ⁇ m 2 /s ⁇ 3 )
- ⁇ is the fluid density (in kg/m 3 );
- N i is the rotation rate of the CSTR impeller (in s ⁇ 1 );
- D i is the diameter of the CSTR impeller (in m).
- the power number describes the relationship between the power applied to the impeller in a CSTR and the force exerted by the fluid in the CSTR resisting the movement of the impeller.
- the power number for a CSTR filled with a particular fluid may be compared to the Reynolds number for said CSTR, for example with a plot of power number as a function of Reynolds number. For relatively low values for the Reynolds number (i.e. for Reynolds numbers corresponding to laminar mixing conditions), the power number decreases as Reynolds number increases. For relatively high values for the Reynolds number (i.e. for Reynolds numbers corresponding to turbulent mixing conditions), the power number remains about constant as the Reynolds number increases.
- a cannabinoid solution within a CSTRs may be characterized by a minimum Reynolds number above which the power number remains about constant.
- said minimum Reynolds number defines conditions that may ensure turbulent mixing.
- crystal In the context of the present disclosure, the terms “crystal”, “crystallizing”, “crystalline”, and the like are used broadly to refer to a spectrum of solid materials having a degree of microscopic order but not necessarily a highly ordered crystal lattice that extends in all directions. As will be appreciated by those skilled in the art who have benefitted from the teachings of the present disclosure, the degree of crystallinity of material can be evaluated by a variety of means such as but not limited to powder X-ray diffraction, single-crystal X-ray diffraction, differential scanning calorimetry, and the like.
- the cannabinoid-rich solution may be prepared from a distillate, a resin, an extract, or the like.
- the cannabinoid-rich solution may be prepared by solvent extraction from marijuana or hemp.
- the extraction solvent may be supercritical carbon dioxide, ethanol, heptane, pentane, propane, n-butane, iso-butane, or any Class 3 solvent as defined by the International Conference on Harmonization (ICH) guidelines.
- the solvent extract (or the cannabinoid-rich solution more generally) may be further refined using purification processes including but not limited to filtration, winterization (i.e. precipitation of undesired plant waxes using organic solvent at or below ambient temperature), distillation, chromatography (e.g. normal-phase, reversed-phase, centrifugal partition, simulated moving bed), trituration, liquid-liquid extraction, and solid-liquid extraction.
- the cannabinoids in the cannabinoid-rich solution may also be of synthetic origin.
- the cannabinoids of the cannabinoid-rich solution may also be combined with an excipient(s) (e.g. basic molecules, acidic molecules, co-formers, derivatization agents) prior to crystallization to modify the physical and/or chemical properties of the cannabinoids and/or the cannabinoid-rich solution.
- excipient(s) e.g. basic molecules, acidic molecules, co-formers, derivatization agents
- cannabinoids may be incubated with a basic molecule, such as an alkaloid or basic amino acid, to form the carboxylate salt of the cannabinoid of interest. This modification may serve to improve the crystallization process and/or to modify the physical/chemical properties of the cannabinoid of interest.
- Cannabinoids of the cannabinoid-rich solution may also be combined with acidic molecules and/or co-formers prior to crystallization to form a co-crystal with the cannabinoid of interest during the crystallization process. This modification may serve to improve the crystallization process and/or to modify the physical/chemical properties of the cannabinoid of interest.
- Cannabinoids of the cannabinoid-rich solution may also be combined with derivatization agents prior to crystallization to form a chemical derivative of the cannabinoid of interest. This modification may serve to improve the crystallization process and/or to modify the physical/chemical properties of the cannabinoid of interest.
- tetrahydrocannabinol THC is an oil under ambient conditions and does not readily crystallize.
- Functionalization of the phenolic hydroxyl group of THC with certain ester or sulfonic ester moieties may enable crystallization of otherwise non-crystallisable cannabinoids including but not limited to ⁇ 9 -tetrahydrocannabinol, ⁇ 8 -tetrahydrocannabinol, and/or cannabinol.
- esters of acidic cannabinoids made by synthetic means can be used as the cannabinoids in the cannabinoid cannabinoid-rich solution.
- cannabinoid refers to: (i) a chemical compound belonging to a class of secondary compounds commonly found in plants of genus Cannabis , (ii) synthetic cannabinoids and any enantiomers thereof; and/or (iii) one of a class of diverse chemical compounds that may act on cannabinoid receptors such as CB1 and CB2.
- the cannabinoid is a compound found in a plant, e.g., a plant of genus Cannabis , and is sometimes referred to as a phytocannabinoid.
- a phytocannabinoid One of the most notable cannabinoids of the phytocannabinoids is tetrahydrocannabinol (THC), the primary psychoactive compound in Cannabis .
- Cannabidiol (CBD) is another cannabinoid that is a major constituent of the phytocannabinoids.
- CBD cannabidiol
- the cannabinoid is a compound found in a mammal, sometimes called an endocannabinoid.
- the cannabinoid is made in a laboratory setting, sometimes called a synthetic cannabinoid.
- the cannabinoid is derived or obtained from a natural source (e.g. plant) but is subsequently modified or derivatized in one or more different ways in a laboratory setting, sometimes called a semi-synthetic cannabinoid.
- a cannabinoid can be identified because its chemical name will include the text string “*cannabi*”.
- cannabinoids that do not use this nomenclature, such as for example those described herein.
- any and all isomeric, enantiomeric, or optically active derivatives are also encompassed.
- reference to a particular cannabinoid includes both the “A Form” and the “B Form”.
- THCA has two isomers, THCA-A in which the carboxylic acid group is in the 1 position between the hydroxyl group and the carbon chain (A Form) and THCA-B in which the carboxylic acid group is in the 3 position following the carbon chain (B Form).
- first cannabinoid may refer to: (ii) salts of acid forms, such as Na + or Ca 2+ salts of such acid forms; and/or (iii) ester forms, such as formed by hydroxyl-group esterification to form traditional esters, sulphonate esters, and/or phosphate esters.
- cannabinoids include, but are not limited to, Cannabigerolic Acid (CBGA), Cannabigerolic Acid monomethylether (CBGAM), Cannabigerol (CBG), Cannabigerol monomethylether (CBGM), Cannabigerovarinic Acid (CBGVA), Cannabigerovarin (CBGV), Cannabichromenic Acid (CBCA), Cannabichromene (CBC), Cannabichromevarinic Acid (CBCVA), Cannabichromevarin (CBCV), Cannabidiolic Acid (CBDA), Cannabidiol (CBD), ⁇ 6-Cannabidiol ( ⁇ 6-CBD), Cannabidiol monomethylether (CBDM), Cannabidiol-C4 (CBD-C4), Cannabidivarinic Acid (CBDVA), Cannabidivarin (CBDV), Cannabidiorcol (CBD-C1), Tetrahydrocannabinolic acid A (C
- THC refers to tetrahydrocannabinol. “THC” is used interchangeably herein with “ ⁇ 9-THC”.
- the first cannabinoid may comprise THC ( ⁇ 9-THC), THCA, ⁇ 8-THC, trans- ⁇ 10-THC, cis- ⁇ 10-THC, THCV, THCVA, ⁇ 8-THCV, ⁇ 9-THCV, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, CBLVA CBT, CBTA, or cannabicitran.
- Structural formulae of cannabinoids of the present disclosure may include the following:
- the first cannabinoid may comprise CBD, CBDV, CBC, CBCV, CBG, CBGV, THC, THCV, or a regioisomer thereof.
- regioisomers refers to compounds that differ only in the location of a particular functional group.
- the first cannabinoid is CBD.
- the first cannabinoid is ⁇ 9 -THC or ⁇ 10 -THC.
- inducing a cannabinoid-rich solution into a supersaturated state is useful for promoting continuous cannabinoid crystallization.
- the inducing of the cannabinoid-rich solution to the supersaturated state may precede the mixing the cannabinoid-rich solution within the CSTR.
- the inducing of the cannabinoid-rich solution to the supersaturated state may be concurrent with the mixing the cannabinoid-rich solution within the CSTR.
- the supersaturation of a cannabinoid-rich solution may be induced by controlled temperature reduction.
- the methods of the present disclosure may further comprise cooling the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof either before or within the CSTR.
- the cannabinoid-rich solution may comprise cannabidiol (CBD) with a CBD concentration of about 1 g/mL of solvent.
- CBD cannabidiol
- the cannabinoid-rich solution may have a temperature of between about 0° C. and about 50° C. at an inlet to the CSTR.
- supersaturation of a cannabinoid-rich solution may be induced by evaporation.
- the methods of the present disclosure may further comprise evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR to reduce the volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof to between 80% and 20% of the initial volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof.
- the cannabinoid-rich solution may have a viscosity of between about 0.05 cP and about 250 cP at an inlet to the CSTR.
- the cannabinoid-rich solution may comprise CBD and have a viscosity of about 1.0 cP.
- the cannabinoid-rich solution may have a fluid density of between about 0.2 g/mL and about 1,700 g/mL at an inlet to the CSTR.
- the cannabinoid-rich solution may comprise CBD and have a fluid density of about 1.0 g/mL.
- the cannabinoid-rich solution may have a temperature of between about 0° C. and about 80° C. at an inlet to the CSTR.
- the cannabinoid-rich solution may comprise CBD and have a temperature of about 50° C.
- the CSTR may be cylindrical in shape.
- the impeller may be positioned and oriented to align the axis of rotation of the impeller in a direction parallel to the cylinder axis of the CSTR.
- the impeller may be laterally offset from the center of the CSTR with an offset distance equal to one sixth the diameter of the CSTR.
- the impeller may have an impeller diameter equal to one third the diameter of the CSTR.
- mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with a Rushton turbine, a propeller, an anchor impeller, a gate-anchor impeller, a paddle impeller, a helical-screw impeller, a helical-ribbon impeller, or a combination thereof.
- mixing the cannabinoid-rich solution with a propeller and/or a Rushton turbine may be advantageous when the viscosity of the cannabinoid-rich solution is below 10,000 centipoise.
- turbulent mixing conditions within a CSTR give rise to turbulent eddies with a length scale that may be quantified by the Kolmogarov length scale ⁇ as defined as by EQN. 3 and EQN. 4.
- ⁇ is the fluid kinematic viscosity (in m 2 /s);
- ⁇ is the energy dissipation rate (kg/m ⁇ s);
- P is the input power (in kg ⁇ m 2 /s ⁇ 3 );
- ⁇ is the fluid density (in kg/m 3 );
- D i is the diameter of the CSTR impeller (in m).
- mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with an energy dissipation rate to produce eddies with a Kolmogorov length scale larger than the size of the crystalline cannabinoid particles.
- the Kolmogarov length scale of eddies within the CSTR decreases.
- Turbulent eddies smaller than the size of the crystalline cannabinoid particles may apply shear forces to the crystalline cannabinoid particles and thereby damage the crystalline cannabinoid particles.
- the tubular CSTR may comprise a baffle that is shaped, oriented, and positioned to redirect flow within the CSTR.
- the baffle may be shaped, positioned, and oriented to redirect swirling flow within the CSTR to convert said swirling flow into turbulent flow.
- the baffle may be one of a plurality of baffles.
- the severity of the turbulent mixing conditions required to induce crystal nucleation/growth from a particular cannabinoid-rich solution will vary depending on the particulars of the cannabinoid rich solution and the extent of supersaturation.
- the critical Reynolds number may be greater than 500, 1,000, or 10,000.
- the diameter and/or shape of the impeller and the size and shape of the reactor may impact the critical Reynolds number, and these parameters can take any of a variety of forms provided that turbulent mixing conditions are achieved within the CSTR.
- the diameter and/or the capacity of the CSTR is not limited to any particular value and can vary, provided that turbulent mixing conditions are achieved within the CSTR.
- the flow rate may be characterized as a linear flow rate, wherein the flow-rate is expressed in linear velocity units such as meters per second (m/s).
- the flow rate may be expressed as a volumetric flow rate.
- flow rates may be expressed in volumetric velocity units such as liters per hour (L/h).
- Flow rates may also be expressed as a ratio of the total volume of the CSTR divided by the volumetric flow rate, for example the average residence time of fluid within the reactor (h).
- the flow rate may be characterized as the flow rate through an inlet to the CSTR.
- the flow rate may be characterized as the flow rate through an outlet to the CSTR.
- the cannabinoid-rich solution may comprise a solvent.
- the solvent may comprise pentane, hexane, heptane, methanol, ethanol, isopropanol, dimethyl sulfoxide, acetone, ethyl acetate, diethyl ether, tert-butyl methyl ether, water, acetic acid, anisole, 1-butanol, 2-butanol, butane, butyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, propane, propyl acetate, trimethylamine, or a combination thereof.
- the methods of the present disclosure further comprise dispersing a plurality of seed crystals into the cannabinoid-rich solution concurrent with the mixing the cannabinoid-rich solution.
- a seed crystal dispersion comprises at least one seed crystal dispersed in at least one solvent.
- a seed crystal is a crystal with a size smaller than the crystal size of the desired product. Addition of seed crystals may be advantageous as the presence of seed crystals obviates the need for nucleation during crystallization, and so long as the seed crystal size and size distribution remain constant the size and size distribution of the resulting crystalline cannabinoid particles will remain constant. Variations in the rate of nucleation contribute to variation in size distribution, therefore obviating the need for nucleation may increase the reliability of the crystallization.
- Crystalline cannabinoids produced by continuous crystallization can be modified by means of salt formation, co-crystallization, derivatization (e.g. esterification, etherification, isomerization, alkylation, arylation, oxidation, reduction, ring-opening/ring-closing reactions).
- Previously crystallized material can be further purified by recrystallization using CSTR to obtain enhanced cannabinoid purity. Recrystallization may also be conducted on modified crystal forms (e.g. carboxylate salts, co-crystals, synthetic derivatives) originally obtained by continuous crystallization.
- the methods of the present disclosure further comprise flowing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution into an additional CSTR, mixing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution to form a plurality of larger crystalline cannabinoid particles within the additional CSTR, and discharging the plurality of larger crystalline cannabinoid particles and the cannabinoid-depleted solution from the additional CSTR in a continuous manner to provide a flow rate through the additional CSTR.
- Separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may include separating the larger crystalline cannabinoid particles from plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution.
- the methods of the present disclosure further comprise flowing, mixing, and discharging through a plurality of additional CSTRs in a manner substantively similar to the method described above. Operating multiple CSTRs in series, as described above, may provide near-plug flow conditions since a plurality of CSTRs possess a narrower residence time distribution than a single CSTR with a capacity equal to the total capacity of the plurality of CSTRs.
- FIG. 1 to FIG. 3 show representations of the physical structures and methods for continuously crystallizing cannabinoids according to the present disclosure.
- FIG. 1 shows a schematic diagram of an exemplary CSTR 100 which may be employed in executing a method in accordance with the present disclosure.
- CSTR 100 comprises reaction vessel 110 , inlet 112 , outlet 114 , additional inlet 116 , a plurality of baffles 118 , impeller 120 , axle 122 , motor 124 , jacket 130 , jacket inlet 132 , and jacket outlet 134 .
- Reactor vessel 110 comprises a reactor vessel wall to define a volume within which crystallization may occur.
- Reactor vessel 110 may comprise impermeable and generally chemically inert materials, for example glass or stainless steel.
- Reactor vessel 110 possesses a cylindrical shape and a reactor vessel diameter 128 .
- Impeller 120 is positioned and oriented to align the axis of rotation of the impeller with the cylinder axis of reactor vessel 110 .
- Reactor vessel 110 may be completely filled with fluid. Alternatively, reactor vessel may be partially filled with fluid, with the remaining volume filled with gas.
- the gas-filled volume may be referred to as head space, and the head space may be filled with inert gas, for example argon or nitrogen.
- the fluid within reactor vessel 110 may completely immerse impeller 120 , where immersing impeller 120 may be advantageous to ensure effective mixing of the fluid within reactor vessel 110 .
- Impeller 120 , axle 122 , and motor 124 may be referred to collectively as a mixer. Impeller 120 is physically coupled to axle 122 . Axle 122 is physically coupled to motor 124 . Axle 122 may be physically coupled motor 124 by gears, a pulley, a transmission, or by directly coupling axle 122 to a drive shaft of motor 124 . Directly physically coupling axle 122 to a drive shaft of motor 124 may include welding, bolting, and/or adhering axle 122 to a drive shaft of motor 124 . Axle 122 passes through the wall of reactor vessel 110 . Axle 122 may pass through the wall of reactor vessel 110 via a seal. Impeller 120 comprises a paddle impeller.
- Impeller 120 Power may be applied to motor 124 , causing motor 124 to turn impeller 120 via axle 122 .
- the rate at which motor 124 turns impeller 120 comprises a mixing speed N.
- Impeller 120 has an impeller diameter 126 . Turning impeller 120 causes the outermost tip of impeller 120 to turn with a velocity that depends on the mixing speed N and impeller diameter 126 . Fluid in contact with impeller 120 while impeller 120 turns will flow, with the nature of said flow depending on the geometry of reactor vessel 110 , the mixing speed N, and impeller diameter 126 .
- Impeller diameter 126 may advantageously be about one third of reactor vessel diameter 128 to maximize mixing efficiency.
- Inlet 112 comprises a channel between reactor vessel 110 and the exterior of reactor vessel 110 through which fluids may pass.
- Inlet 112 comprises a tube passing through the wall of reactor vessel 110 .
- the exterior side of inlet 112 may comprise a fitting to which a hose or a pipe may be attached.
- the reactor vessel side of inlet 112 may comprise a nozzle to direct the flow of fluid through inlet 112 into reactor vessel 110 in a single direction, for example downwards to fall into a layer of fluid within reactor vessel 112 , or along the wall of reactor vessel 110 . While inlet 112 is depicted in FIG. 1 as being located at the top of reactor vessel 110 , those skilled in the art will appreciate that inlet 112 may be relocated to a variety of suitable locations in reactor vessel 110 provided that fluids are able to flow into reactor vessel 110 through inlet 112 .
- Outlet 114 comprises a channel between reactor vessel 110 and the exterior of reactor vessel 110 through which fluids may pass.
- Outlet 114 comprises a tube passing through the wall of reactor vessel 110 .
- the exterior side of outlet 114 may comprise a fitting to which a hose or a pipe may be attached. While outlet 114 is depicted in FIG. 1 as being located at the bottom of reactor vessel 110 , those skilled in the art will appreciate that outlet 114 may be relocated to a variety of suitable locations in reactor vessel 110 provided that fluids may be discharged from reactor vessel 110 through outlet 114 .
- each of the plurality of baffles 118 is physically coupled to the interior of reactor vessel 110 .
- Each of the plurality of baffles 118 is shaped, positioned, and oriented within reactor vessel 110 to redirect the flow of fluid within reactor vessel 110 .
- turning impeller 120 may cause fluid to adjacent to the walls of reactor vessel 110 (and therefore furthest from impeller 120 ) to swirl (i.e. undergo laminar flow in a direction parallel to the walls of reactor vessel 110 ).
- Plurality of baffles 118 are positioned perpendicular to the direction of said flow, causing said laminar flow to be diverted away from the wall of reactor vessel 110 and thereby cause said flow to become turbulent.
- Jacket 130 surrounds reactor vessel 110 .
- Jacket 130 forms a space around reactor vessel 110 through which a thermal fluid may be circulated.
- Jacket 130 comprises thermal fluid inlet 132 through which thermal fluid may enter jacket 130 .
- Jacket 130 comprises thermal fluid outlet 134 through which thermal fluid may exit jacket 130 .
- Thermal fluid circulating through jacket 130 may be thermally coupled to reactor vessel 110 , thereby allowing heat transfer between a thermal fluid and reactor vessel 110 .
- Reactor vessel 110 may be thermally coupled to fluids within reactor vessel 110 .
- jacket 130 may allow heating and/or cooling of a fluid within reactor vessel 110 .
- FIG. 2 shows a schematic diagram of two exemplary CSTRs 100 linked in series. Fluid flow in FIG. 2 is depicted by a dashed line. Fluid may enter a first CSTR 100 through a first inlet 112 . Fluid may then be mixed by a first mixer comprising a first motor 124 , first axle 122 , and first impeller 120 . Fluid may then exit first CSTR 100 via first outlet 114 . Fluid may then enter a second CSTR 100 through a second inlet 112 . Fluid may then be mixed by a second mixer comprising a second motor 124 , second axle 122 , and second impeller 120 . Fluid may then exit second CSTR 100 via second outlet 114 . First outlet 114 may be fluidically coupled to second inlet 112 via a pipe, a hose, a pump, or the like.
- FIG. 3 shows a flow diagram for a method 300 for continuously preparing crystalline cannabinoid particles.
- Method 300 comprises six steps: preparing a cannabinoid-rich solution that comprises a first cannabinoid (step 302 ); inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid (step 304 ); flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner (step 306 ); mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR (step 308 ); discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the
- the turbulent mixing conditions are defined by a Reynolds number that is greater than a critical Reynolds number for the cannabinoid-rich solution and the CSTR.
- a first cannabinoid-rich solution that comprises a first cannabinoid is prepared.
- the cannabinoid-rich solution may comprise a cannabinoid extract, a cannabinoid resin, a cannabinoid distillate, a cannabinoid isolate, or a combination thereof.
- the first cannabinoid may be ⁇ 9 -tetrahydrocannabinolic acid, ⁇ 9 -tetrahydrocannabinol, ⁇ 8 -tetrahydrocannabinolic acid, ⁇ 8 -tetrahydrocannabinol, cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabichromenic acid, cannabichromene, cannabinolic acid, cannabinol, ⁇ 9 -tetrahydrocannabivarinic acid, ⁇ 9 -tetrahydrocannabivarin, cannabigerivarin, cannabidivarin, cannabichromevarin, 11-hydroxy- ⁇ 9 -tetrahydrocannabinol, 11-nor-9-carboxy- ⁇ 9 -tetrahydrocannabinol, or a combination thereof.
- the cannabinoid-rich solution may comprise ⁇ 9 -tetrahydrocannabinolic acid, ⁇ 9 -tetrahydrocannabinol, ⁇ 8 -tetrahydrocannabinolic acid, ⁇ 8 -tetrahydrocannabinol, cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabichromenic acid, cannabichromene, cannabinolic acid, cannabinol, ⁇ 9 -tetrahydrocannabivarinic acid, ⁇ 9 -tetrahydrocannabivarin, cannabigerivarin, cannabidivarin, cannabichromevarin, 11-hydroxy- ⁇ 9 -tetrahydrocannabinol, 11-nor-9-carboxy- ⁇ 9 -tetrahydrocannabinol, or a combination thereof.
- the cannabinoid-rich solution may comprise a solvent.
- the solvent may comprise pentane, hexane, heptane, methanol, ethanol, isopropanol, dimethyl sulfoxide, acetone, ethyl acetate, diethyl ether, tert-butyl methyl ether, water, acetic acid, anisole, 1-butanol, 2-butanol, butane, butyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, propane, propyl acetate, trimethylamine, or a combination thereof.
- the cannabinoid-rich solution may further comprise an excipient.
- the cannabinoid-rich solution may comprise a solvent, or a mixture of solvents.
- a mixture of solvents may be advantageous to achieve a desired nucleation or crystal growth rate.
- the solvent may comprise a Class III solvent, where Class III solvents are advantageous for active pharmaceutical ingredient preparation due to their low toxicity.
- the cannabinoid-rich solution is induced to a supersaturated state.
- a solvent is supersaturated when the concentration of solute in a given solution is above the solubility limit for said solution.
- the degree of supersaturation of a solution comprises the amount by which the concentration of the supersaturated solution exceeds the saturation concentration of said supersaturated solution.
- the degree of supersaturation may be expressed in absolute units (e.g. moles/liter or grams/liter) or in relative units (e.g. [solute concentration]/[saturation concentration] ⁇ 100%).
- Supersaturating a cannabinoid solution may include causing a solution to possess a solute concentration above the solubility limit of the solvent.
- solubility limit of a given cannabinoid solution depends on at least the temperature of the solution, the cannabinoid in question, the solvent in question, and the presence of any non-solvents.
- Non-exclusive methods by which a solution may be supersaturated include cooling, evaporation, and adding a non-solvent.
- the saturation concentration of a cannabinoid in a solvent depends on the temperature of the solution, with a higher temperature typically yielding a higher saturation concentration.
- a saturated solution may be prepared by combining an excess amount a solid (i.e. undissolved) cannabinoid with a solvent at a temperature equal to the boiling point of the solid. A portion of the cannabinoid will dissolve in the solvent, with the excess being unable to dissolve due to saturation of the solvent with dissolved cannabinoid. The undissolved solid cannabinoid may then be separated from the cannabinoid solution to yield a saturated cannabinoid solution. Cooling of said saturated solution will decrease the solubility limit of the solvent, and since the amount of cannabinoid dissolved in the solution is now above the new solubility limit the solution becomes supersaturated by cooling.
- the saturation concentration of a cannabinoid in a solvent depends on the composition of the solvent.
- the solvent may comprise a mixture of solvents, where the mixture of solvents may comprise at least one cannabinoid solvent and at least one cannabinoid non-solvent.
- a cannabinoid solvent is a solvent that is able to dissolve at least twice the amount of the cannabinoid as the cannabinoid non-solvent.
- the cannabinoid may be dissolved in the cannabinoid solvent to saturate the cannabinoid solvent, then the cannabinoid solution may be mixed with the cannabinoid non-solvent to form the mixture of solvents.
- the presence of the non-solvent decreases the saturation concentration of the cannabinoid in the mixture of solvents.
- the mixture of solvents may therefore become supersaturated by decreasing the saturation concentration of the cannabinoid in the mixture of solvents below the actual concentration of the cannabinoid in the mixture.
- the cannabinoid-rich solution is flowed into a CSTR ( 100 ) in a continuous manner.
- the CSTR ( 100 ) may comprise a reaction vessel ( 110 ), an inlet ( 112 ) comprising an opening in the reaction vessel ( 110 ) through which the first cannabinoid solution flows, an outlet ( 114 ), an additional inlet ( 116 ), a baffle ( 118 ), a mixer comprising an impeller ( 120 ), an axle ( 122 ), and a motor ( 124 ), and a jacket ( 130 ) comprising a jacket inlet ( 132 ), and jacket outlet ( 134 ).
- the baffle ( 118 ) may be shaped, oriented, and/or positioned to redirect flow within the CSTR.
- the baffle ( 118 ) may be one of a plurality of baffles ( 118 ).
- the CSTR ( 100 ) may be cylindrical, and the impeller ( 120 ) may be positioned and oriented to align the axis of rotation of the impeller with the cylinder axis.
- the cannabinoid-rich solution may have a viscosity of between about 0.05 and about 250 cP at an inlet ( 112 ) to the CSTR.
- the cannabinoid-rich solution may have a fluid density of between about 0.02 g/mL and about 1,700 g/mL at an inlet ( 112 ) to the CSTR.
- the cannabinoid-rich solution may have a temperature of between about 0° C. and about 80° C. at an inlet ( 112 ) to the CSTR.
- the cannabinoid-rich solution is mixed under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR ( 100 ).
- the cannabinoid-rich solution may mixed under turbulent mixing conditions with a mixer comprising an impeller ( 120 ), an axle ( 122 ), and a motor ( 124 ).
- the critical Reynolds number may be about equal to a Reynolds number above which a power number for the reactor is about constant.
- the critical Reynolds number may be greater than 10,000.
- Mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with an impeller ( 120 ), the impeller comprising a Rushton turbine, a propeller, an anchor impeller, a gate-anchor impeller, a paddle impeller, a helical screw impeller, a helical ribbon impeller, or any combination thereof.
- Mixing the cannabinoid-rich solution with the mixer may include turbulently mixing the cannabinoid-rich solution with the mixer wherein the impeller diameter ( 126 ) is about one third the diameter of the CSTR ( 128 ).
- Mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with an energy dissipation rate to produce eddies with a Kolmogorov length scale larger than the size of the crystalline cannabinoid particles.
- Crystallization may occur in a supersaturated solution via homogeneous nucleation.
- homogeneous nucleation dissolved individual solute molecules may encounter other dissolved individual solute molecules in a supersaturated solution and agglomerate together to form a small crystal nucleus.
- the crystal nucleus may then grow larger as additional solute molecules encounter and thereby attach to the surface of the crystal nucleus.
- the surface of the crystal is typically unstable, and thermodynamic instability provides an energy barrier to growth.
- the surface area to volume ratio is small which negates the energy barrier and causes crystal growth to be thermodynamically favorable, making large crystal nuclei stable.
- the rate of nucleation is the rate at which stable crystal nuclei form.
- a stable crystal nucleus may grow effectively indefinitely to form a large crystal.
- Small crystal nuclei have a high surface area to volume ratio which causes the energy barrier to growth to become significant, which makes dissolution of the small crystal nuclei thermodynamically favorable and causes small nuclei to be unstable.
- dissolution of the small nuclei is favored, there exists a non-zero statistical probability that a small nucleus will grow to large enough to become stable and eventually grow to become a large crystal.
- the probability of an unstable crystal nucleus growing large enough to become stable, and thereby the rate of formation of stable crystal nuclei increases as the degree of supersaturation of the solution increases.
- the amount of time required to form at least one stable crystal nucleus may be on the order of second, hours, days, or months.
- Crystallization may occur in a supersaturated solution via heterogeneous nucleation.
- seed crystals are added to the supersaturated solution. Dissolved individual solute molecules may encounter and thereby attach to the surface of the seed crystal, causing the seed crystal to grow and eventually form a large crystal.
- a seed crystal may comprise the same material as the solute, or a different material from the solute.
- seed crystals may be produced by milling the crystalline product of a previous crystallization to produce a large number of small seed crystals composed of the same material as the product to be crystallized. The presence of seed crystals in the supersaturated solution allows crystal growth to occur without the need for homogeneous nucleation. Homogeneous nucleation may require a relatively high degree of supersaturation.
- Inducing of the cannabinoid-rich solution to the supersaturated state may precedes the mixing the cannabinoid-rich solution. Inducing of the cannabinoid-rich solution to the supersaturated state may be concurrent with the mixing the cannabinoid-rich solution.
- a narrow size distribution may be advantageous since a continuous separation method may be optimised to separate particles of a certain size and a narrow size distribution ensures the maximum number are of the optimal size. Crystalline cannabinoid particles with a size that closely matches the expected size will therefore also be closest to the optimal size of the separation method.
- the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution are discharged from the CSTR ( 100 ) in a continuous manner to provide a flow rate through the CSTR.
- the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may be discharged via an outlet ( 114 ).
- the crystalline cannabinoid particles are separated from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution in a continuous manner.
- Continuous separation may include centripetal separation, filter separation, and settling.
- continuously separating crystalline cannabinoid particles is more efficient when the size and size distribution of the crystalline cannabinoid particles closely matches the size for which the separation method has been optimised.
- Separating the crystalline cannabinoid particles from the cannabinoid-depleted solution may include forming a mother liquor.
- the method 300 may further comprise reducing the volume of the mother liquor to form a concentrated mother liquor and a recycled solvent.
- the method 300 may further comprise mixing the concentrated mother liquor with a second cannabinoid solution to form a follow-on quantity of cannabinoid-rich solution.
- the follow-on quantity of cannabinoid-rich solution may comprise at least a portion of the first cannabinoid. Mixing the concentrated mother liquor with the second cannabinoid solution to form the follow-on quantity of cannabinoid-rich solution may increase the efficiency of the crystallization, since a portion of the dissolved cannabinoid that was not initially crystallized may crystallize when the concentrated mother liquor passes through the CSTR ( 100 ).
- the method 300 may further comprise dissolving at least a portion of the cannabinoid in the recycled solvent to form a third cannabinoid solution, dissolving the remainder of the cannabinoid in the solvent to form a fourth cannabinoid solution, and mixing the third and fourth cannabinoid solution to form the first cannabinoid solution.
- Using the recycled solvent to form the first cannabinoid solution decreases the cost of the crystallization since some of the solvent used for the crystallization may be re-used.
- the method 300 may further comprise cooling the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR.
- the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR may be cooled by flowing a thermal fluid into a jacket ( 130 ) through a jacket inlet ( 132 ) and a jacket outlet ( 134 ).
- the method 300 may further comprise dispersing a plurality of seed crystals into the cannabinoid-rich solution concurrent with the mixing the cannabinoid-rich solution.
- the plurality of seed crystals may be dispersed into the cannabinoid-rich solution by flowing a dispersion comprising the plurality of seed crystals through an additional inlet ( 116 ).
- the plurality of seed crystals may be dispersed into the cannabinoid-rich solution by mixing a dispersion comprising the plurality of seed crystals with the cannabinoid-rich solution.
- the method 300 may further comprise evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR to reduce the volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof to between 80% and 20% of the initial volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof.
- Evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof may include evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof under reduced pressure.
- the method 300 may further comprise flowing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution into an additional CSTR ( 100 ), mixing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution to form a plurality of larger crystalline cannabinoid particles within the additional CSTR ( 100 ), and discharging the plurality of larger crystalline cannabinoid particles and the cannabinoid-depleted solution from the additional CSTR ( 100 ) in a continuous manner to provide a flow rate through the additional CSTR ( 100 ).
- Separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may include separating the larger crystalline cannabinoid particles from plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution.
- the term “about” refers to an approximately +/ ⁇ 10% variation from a given value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
- compositions and methods are described in terms of “comprising,” “containing,” or “including” various components or steps, the compositions and methods can also “consist essentially of or “consist of the various components and steps.
- indefinite articles “a” or “an,” as used in the claims, are defined herein to mean one or more than one of the element that it introduces.
- ranges from any lower limit may be combined with any upper limit to recite a range not explicitly recited, as well as, ranges from any lower limit may be combined with any other lower limit to recite a range not explicitly recited, in the same way, ranges from any upper limit may be combined with any other upper limit to recite a range not explicitly recited.
- any numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range are specifically disclosed.
- every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values even if not explicitly recited.
- every point or individual value may serve as its own lower or upper limit combined with any other point or individual value or any other lower or upper limit, to recite a range not explicitly recited.
Abstract
Description
- This application claims priority to and benefit of U.S. Provisional Patent Application Ser. No. 62/877,071 filed on Jul. 22, 2019, which is hereby incorporated by reference.
- The present disclosure generally relates to methods of crystallizing cannabinoids. In particular, the present disclosure relates to continuous-mode cannabinoid-crystallization methods as opposed to batch-mode cannabinoid-crystallization methods.
- Cannabinoids are often defined in pharmacological terms as a class of compounds that exceed threshold-binding affinities for specific receptors found in central-nervous-system tissues and/or peripheral tissues. The interactions between cannabinoids and their receptors are under active investigation by a number of researchers, because the resultant effects are demonstrably important both in medicinal and reactional contexts. Many medicinal and recreational cannabinoid products feature cannabinoids in crystalline form. Methods for producing such products typically rely on batch-mode crystallization protocols. Unfortunately, batch-mode crystallization protocols are difficult to control—especially at large scale—and they are often associated with inconsistent product specifications (such as crystal-size distribution, polymorphic form, and/or crystal morphology). Such inconsistent product specifications may negatively impact downstream processes and/or consumer experiences in both medicinal and recreational contexts.
- In recent years, continuous crystallization technologies have emerged as viable alternatives to batch-mode crystallization technologies. Continuous-crystallization methods are associated with efficient use of solvents, energy, and space, and they are associated with minimal waste production. Continuous stirred-tank reactors (CSTRs) are a type of reactor that can be configured to operate in a manner that is suitable for inducing crystallization in a continuous-mode process. Continuous-crystallization methods may be designed towards providing near plug-flow conditions (i.e. conditions under which a fluid flows with minimal shearing between adjacent layers) by operating multiple CSTRs in series.
- CSTRs typically feature an impeller and baffles to provide turbulent agitation to fluid within the CSTR. Fluid turbulence in a CSTR is associated with continuous generation of swirling eddy currents due to fluid-impeller and/or fluid-baffle interactions. The fluid mechanics associated with such conditions are highly complex in that there are a number of confounding variables contributing to turbulent mixing conditions (e.g. impeller geometry, impeller speed, impeller location within the CSTR, baffle spacing, baffle geometry, baffle orientation, fluid viscosity, etc.). At the same time, there are number of confounding variables that impact the pre-crystallization behavior of a solution as it transitions from an undersaturated state to a supersaturated state. Likewise, there are a number of confounding variables that impact crystal nucleation and crystal growth. Accordingly, it is difficult to predict the particular physical-chemical parameters and mixing conditions that will navigate the meta-stable states required to induce continuous crystallization of a particular type of material from a particular solution. Researchers are often confounded when applying systematic approaches to continuously crystallizing target compounds from CSTRs, and this is particularly true for complex mixtures of structurally similar compounds (e.g. regioisomers, stereoisomers, etc.) such as those associated with cannabinoid extracts, resins, distillates, crude isolates, and the like. Accordingly, methods for crystallizing cannabinoids under continuous-flow conditions to provide particular crystal-size distributions, polymorphic forms, and/or crystal morphologies are desirable.
- In contrast to the batch-mode crystallization methods typically employed for cannabinoid crystallization, the methods of the present disclosure utilize continuous stirred-tank reactors (CSTRs) that are configured for continuous flow under carefully controlled conditions. By modulating the fluid-mechanical parameters of such reactors to exploit the particular solution-phase characteristics of cannabinoids and/or mixtures of cannabinoids, the methods of the present disclosure provide access to a plurality of crystalline cannabinoid materials. In particular, the methods of the present disclosure provide access to crystalline-cannabinoid materials with narrow size distributions, and/or narrow polymorphic distributions. Without being bound to any particular theory, the present disclosure posits that these features are engendered by the utilization of turbulent mixing conditions in a CSTR.
- In select embodiments, the present disclosure relates to a method for producing crystalline cannabinoid particles in continuous mode, the method comprising: preparing a cannabinoid-rich solution that comprises a first cannabinoid; inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid; flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner; mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR; discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the CSTR; and separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution in a continuous manner, wherein the turbulent mixing conditions are defined by a Reynolds number that is greater than a critical Reynolds number for the cannabinoid-rich solution and the CSTR.
- In select embodiments of the present disclosure, the critical Reynolds is about equal to a Reynolds number above which a power number for the reactor is about constant. In select embodiments of the present disclosure, the critical Reynolds number is greater than 10,000.
- In select embodiments of the present disclosure, the CSTR has a capacity between about 30 cc and about 400 L.
- In select embodiments of the present disclosure, mixing the cannabinoid-rich solution under turbulent mixing conditions includes mixing the cannabinoid-rich solution with a Rushton turbine, a propeller, an anchor impeller, a gate-anchor impeller, a paddle impeller, a helical-screw impeller, a helical-ribbon impeller, or a combination thereof.
- In select embodiments of the present disclosure, the CSTR comprises a baffle that is shaped, oriented, or positioned to redirect flow within the CSTR. In select embodiments of the present disclosure, the baffle is one of a plurality of baffles.
- In select embodiments of the present disclosure, the CSTR is cylindrical, the impeller is positioned and oriented to align the axis of rotation of the impeller with the cylinder axis. In select embodiments of the present disclosure, turbulently mixing the cannabinoid-rich solution with the mixer comprises turbulently mixing the cannabinoid-rich solution with the mixer wherein the impeller diameter is about one-third the diameter of the CSTR.
- In select embodiments, the methods of the present disclosure further comprise cooling the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR.
- In select embodiments of the present disclosure, the first cannabinoid is THC (Δ9-THC), THCA, Δ8-THC, trans-Δ10-THC, cis Δ10-THC, THCV, THCVA, Δ8-THCV, Δ9-THCV, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA CBL, CBLA, CBLV, CBLVA, CBT, CBTA, or cannabicitran.
- In select embodiments of the present disclosure, the cannabinoid-rich solution comprises a cannabinoid extract, a cannabinoid resin, a cannabinoid distillate, a cannabinoid isolate, or a combination thereof.
- In select embodiments of the present disclosure, the cannabinoid-rich solution comprises THC (Δ9-THC), THCA, Δ8-THC, trans-Δ10-THC, cis Δ10-THC, THCV, THCVA, Δ8-THCV, Δ9-THCV, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA CBL, CBLA, CBLV, CBLVA, CBT, CBTA, cannabicitran, or a combination thereof.
- In select embodiments of the present disclosure, the cannabinoid-rich solution comprises a solvent. The solvent may comprise pentane, hexane, heptane, methanol, ethanol, isopropanol, dimethyl sulfoxide, acetone, ethyl acetate, diethyl ether, tert-butyl methyl ether, water, acetic acid, anisole, 1-butanol, 2-butanol, butane, butyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, propane, propyl acetate, trimethylamine, or a combination thereof.
- In select embodiments of the present disclosure, the cannabinoid-rich solution has a viscosity of between about 0.05 cP and about 250 cP at an inlet to the CSTR.
- In select embodiments of the present disclosure, the cannabinoid-rich solution has a fluid density of between about 0.2 g/mL and about 1,700 g/mL at an inlet to the CSTR.
- In select embodiments of the present disclosure, the cannabinoid-rich solution has a temperature of between about 0° C. and about 50° C. at an inlet to the CSTR.
- In select embodiments of the present disclosure, the inducing of the cannabinoid-rich solution to the supersaturated state precedes the flowing of the cannabinoid-rich solution through the CSTR.
- In select embodiments of the present disclosure, the inducing of the cannabinoid-rich solution to the supersaturated state is concurrent the mixing of the cannabinoid-rich solution.
- In select embodiments of the present disclosure, the cannabinoid-rich solution further comprises an excipient.
- In select embodiments, the methods of the present disclosure further comprise dispersing a plurality of seed crystals into the cannabinoid-rich solution concurrent with the mixing of the cannabinoid-rich solution.
- In select embodiments, the methods of the present disclosure further comprise flowing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution into an additional CSTR, mixing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution to form a plurality of larger crystalline cannabinoid particles within the additional CSTR, and discharging the plurality of larger crystalline cannabinoid particles and the cannabinoid-depleted solution from the additional CSTR in a continuous manner to provide a flow rate through the CSTR. Separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may include separating the larger crystalline cannabinoid particles from plurality of crystalline cannabinoid particles and/or the cannabinoid-depleted solution.
- In select embodiments of the present disclosure, mixing the cannabinoid-rich solution under turbulent mixing conditions includes mixing the cannabinoid-rich solution with an energy dissipation rate to produce eddies with a Kolmogorov length scale larger than the size of the crystalline cannabinoid particles.
- In select embodiments of the present disclosure, inducing the cannabinoid-rich solution to a supersaturated state includes evaporating at least a portion of the cannabinoid-rich solution.
- These and other features of the present disclosure will become more apparent in the following detailed description in which reference is made to the appended drawings. The appended drawings illustrate one or more embodiments of the present disclosure by way of example only and are not to be construed as limiting the scope of the present disclosure.
-
FIG. 1 shows schematic diagram of an exemplary continuous stirred-tank reactor, which may be employed in executing a method in accordance with the present disclosure. -
FIG. 2 shows a schematic diagram of two exemplary continuous stirred-tank reactors linked in series, which may be employed in executing a method in accordance with the present disclosure. -
FIG. 3 shows a method for continuously preparing crystalline cannabinoid particles in accordance with the present disclosure. - Careful analysis of the solution-phase behavior of a range of cannabinoid solutions indicates that: (i) undersaturated cannabinoid solutions can be induced to supersaturate with strategic manipulation of temperature, pressure, solute, solvent, co-solvent, and/or non-solvent parameters; and (ii) turbulent flow conditions can be used to induce cannabinoid crystallization from supersaturated cannabinoid solution under controlled, repeatable conditions. In the context of the present disclosure the terms “supersaturate” and “supersaturation” refer to a meta-stable state in which a solution comprises a kinetically unstable quantity of solute such that spontaneous nucleation and/or induced nucleation is likely to occur. The methods of the present disclosure leverage the combination of such kinetically unstable solutions with turbulent mixing conditions to induce crystal nucleation and/or growth under controlled, repeatable conditions. The result is a series of methods that provide crystalline cannabinoid materials with narrow crystal-size distributions and consistent polymorphic character. Such crystalline cannabinoids are likely to be useful in both medical and recreational contexts.
- In select embodiments, the present disclosure relates to a method for producing crystalline cannabinoid particles in continuous mode, the method comprising: preparing a cannabinoid-rich solution that comprises a first cannabinoid; inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid; flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner; mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR; discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the CSTR; and separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles, the cannabinoid-depleted solution, or a combination thereof in a continuous manner, wherein the turbulent mixing conditions are defined by a Reynolds number that is greater than a critical Reynolds number for the cannabinoid-rich solution and the CSTR.
- As will be appreciated by those skilled in the art who have benefitted from the teachings of the present disclosure, inducing a cannabinoid-rich solution into a supersaturated state primes the solution for cannabinoid crystallization. Such inducing may be driven by a variety of factors such as temperature decrease, pH adjustment, solute addition, solvent evaporation, co-solvent addition, non-solvent addition, or a combination thereof. Those skilled in the art who have benefitted from the teachings of the present disclosure will appreciate that the particulars of any such strategy for inducing a cannabinoid-rich solution into a supersaturated state will vary, but that the general concepts are similar such that the following discussion of temperature-driven supersaturation may be extrapolated to alternate approaches. With respect to temperature-driven supersaturation of a cannabinoid-rich solution, the particular cannabinoid-rich solution may be characterized by a saturation curve (i.e. a plot of saturation concentration as a function of temperature for a particular pressure) which delineates a boundary between undersaturation and supersaturation conditions. When a hot and undersaturated cannabinoid-rich solution is cooled, it approaches the corresponding point on the saturation curve (i.e. its saturation point). With further cooling, the cannabinoid-rich solution becomes supersaturated, such that the supersaturated solution is in a metastable state, wherein a suitable initiation event will induce nucleation and crystal growth. Nucleation and crystal growth decrease the concentration of the particular cannabinoid (i.e. desupersaturation), and the cannabinoid-rich solution is depleted towards the corresponding point on the saturation curve. While the solubility of the particular cannabinoid in solution may be readily determined experimentally, the supersolubility or the metastable limit for the cannabinoid-rich solution is difficult to define, because it depends on numerous factors such as the rate of supersaturation generation (i.e. cooling rate). Cannabinoid solubility studies indicate that inducing the cannabinoid-rich solution to a supersaturated state in which the particular cannabinoid has a supersaturated concentration that is greater than its corresponding saturation concentration provides sufficient supersaturation for turbulent-flow-induced nucleation and/or growth in a continuous fashion provided the turbulent-flow-related parameters meet particular conditions.
- As will be appreciated by those skilled in the art who have benefited from the teachings of the present disclosure, turbulent mixing conditions within a CSTR may be quantified by the Reynolds number (Re) as defined as by EQN. 1.
-
- Wherein:
- Ni is the rotation rate of the CSTR impeller (in s−1);
- Di is the diameter of the CSTR impeller (in m);
- ρ is the fluid density (in kg/m3); and
- μ is the fluid viscosity (kg/m·s).
- The Reynolds number describes the intensity of mixing within a CSTR equipped with a single impeller. Those skilled in the art who have benefited from the teachings of the present disclosure will readily ascertain the related Reynolds number equations for alternate types of CSTRs. The severity of the turbulent flow conditions required to induce crystal nucleation/growth from a particular cannabinoid-rich solution will vary depending on the particulars of the cannabinoid rich solution and the extent of supersaturation. However, for any particular solution/CSTR combination, there is a critical Reynolds number that defines the minimum conditions required to ensure turbulent mixing.
- As will be appreciated by those skilled in the art who have benefited from the teachings of the present disclosure, turbulent mixing conditions within a CSTR may be further quantified by the Power Number (Np) as defined as by EQN. 2.
-
- Wherein:
- P is the input power (in kg·m2/s−3)
- ρ is the fluid density (in kg/m3);
- Ni is the rotation rate of the CSTR impeller (in s−1); and
- Di is the diameter of the CSTR impeller (in m).
- The power number describes the relationship between the power applied to the impeller in a CSTR and the force exerted by the fluid in the CSTR resisting the movement of the impeller. The power number for a CSTR filled with a particular fluid may be compared to the Reynolds number for said CSTR, for example with a plot of power number as a function of Reynolds number. For relatively low values for the Reynolds number (i.e. for Reynolds numbers corresponding to laminar mixing conditions), the power number decreases as Reynolds number increases. For relatively high values for the Reynolds number (i.e. for Reynolds numbers corresponding to turbulent mixing conditions), the power number remains about constant as the Reynolds number increases. Accordingly, without being bound to any particular theory, the present disclosure posits that a cannabinoid solution within a CSTRs may be characterized by a minimum Reynolds number above which the power number remains about constant. In other words, said minimum Reynolds number defines conditions that may ensure turbulent mixing.
- In the context of the present disclosure, the terms “crystal”, “crystallizing”, “crystalline”, and the like are used broadly to refer to a spectrum of solid materials having a degree of microscopic order but not necessarily a highly ordered crystal lattice that extends in all directions. As will be appreciated by those skilled in the art who have benefitted from the teachings of the present disclosure, the degree of crystallinity of material can be evaluated by a variety of means such as but not limited to powder X-ray diffraction, single-crystal X-ray diffraction, differential scanning calorimetry, and the like.
- The cannabinoid-rich solution may be prepared from a distillate, a resin, an extract, or the like. For example, the cannabinoid-rich solution may be prepared by solvent extraction from marijuana or hemp. The extraction solvent may be supercritical carbon dioxide, ethanol, heptane, pentane, propane, n-butane, iso-butane, or any Class 3 solvent as defined by the International Conference on Harmonization (ICH) guidelines. Optionally, the solvent extract (or the cannabinoid-rich solution more generally) may be further refined using purification processes including but not limited to filtration, winterization (i.e. precipitation of undesired plant waxes using organic solvent at or below ambient temperature), distillation, chromatography (e.g. normal-phase, reversed-phase, centrifugal partition, simulated moving bed), trituration, liquid-liquid extraction, and solid-liquid extraction. The cannabinoids in the cannabinoid-rich solution may also be of synthetic origin.
- The cannabinoids of the cannabinoid-rich solution may also be combined with an excipient(s) (e.g. basic molecules, acidic molecules, co-formers, derivatization agents) prior to crystallization to modify the physical and/or chemical properties of the cannabinoids and/or the cannabinoid-rich solution. For example, cannabinoids may be incubated with a basic molecule, such as an alkaloid or basic amino acid, to form the carboxylate salt of the cannabinoid of interest. This modification may serve to improve the crystallization process and/or to modify the physical/chemical properties of the cannabinoid of interest. Cannabinoids of the cannabinoid-rich solution may also be combined with acidic molecules and/or co-formers prior to crystallization to form a co-crystal with the cannabinoid of interest during the crystallization process. This modification may serve to improve the crystallization process and/or to modify the physical/chemical properties of the cannabinoid of interest.
- Cannabinoids of the cannabinoid-rich solution may also be combined with derivatization agents prior to crystallization to form a chemical derivative of the cannabinoid of interest. This modification may serve to improve the crystallization process and/or to modify the physical/chemical properties of the cannabinoid of interest. For example, tetrahydrocannabinol (THC) is an oil under ambient conditions and does not readily crystallize. Functionalization of the phenolic hydroxyl group of THC with certain ester or sulfonic ester moieties may enable crystallization of otherwise non-crystallisable cannabinoids including but not limited to Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinol, and/or cannabinol. Alternatively, esters of acidic cannabinoids made by synthetic means can be used as the cannabinoids in the cannabinoid cannabinoid-rich solution.
- As used herein, the term “cannabinoid” refers to: (i) a chemical compound belonging to a class of secondary compounds commonly found in plants of genus Cannabis, (ii) synthetic cannabinoids and any enantiomers thereof; and/or (iii) one of a class of diverse chemical compounds that may act on cannabinoid receptors such as CB1 and CB2.
- In select embodiments of the present disclosure, the cannabinoid is a compound found in a plant, e.g., a plant of genus Cannabis, and is sometimes referred to as a phytocannabinoid. One of the most notable cannabinoids of the phytocannabinoids is tetrahydrocannabinol (THC), the primary psychoactive compound in Cannabis. Cannabidiol (CBD) is another cannabinoid that is a major constituent of the phytocannabinoids. There are at least 113 different cannabinoids isolated from Cannabis, exhibiting varied effects.
- In select embodiments of the present disclosure, the cannabinoid is a compound found in a mammal, sometimes called an endocannabinoid.
- In select embodiments of the present disclosure, the cannabinoid is made in a laboratory setting, sometimes called a synthetic cannabinoid. In one embodiment, the cannabinoid is derived or obtained from a natural source (e.g. plant) but is subsequently modified or derivatized in one or more different ways in a laboratory setting, sometimes called a semi-synthetic cannabinoid.
- In many cases, a cannabinoid can be identified because its chemical name will include the text string “*cannabi*”. However, there are a number of cannabinoids that do not use this nomenclature, such as for example those described herein.
- As well, any and all isomeric, enantiomeric, or optically active derivatives are also encompassed. In particular, where appropriate, reference to a particular cannabinoid includes both the “A Form” and the “B Form”. For example, it is known that THCA has two isomers, THCA-A in which the carboxylic acid group is in the 1 position between the hydroxyl group and the carbon chain (A Form) and THCA-B in which the carboxylic acid group is in the 3 position following the carbon chain (B Form). As will be appreciated by those skilled in the art who have benefitted from the teachings of the present disclosure, the terms “first cannabinoid” may refer to: (ii) salts of acid forms, such as Na+ or Ca2+ salts of such acid forms; and/or (iii) ester forms, such as formed by hydroxyl-group esterification to form traditional esters, sulphonate esters, and/or phosphate esters.
- Examples of cannabinoids include, but are not limited to, Cannabigerolic Acid (CBGA), Cannabigerolic Acid monomethylether (CBGAM), Cannabigerol (CBG), Cannabigerol monomethylether (CBGM), Cannabigerovarinic Acid (CBGVA), Cannabigerovarin (CBGV), Cannabichromenic Acid (CBCA), Cannabichromene (CBC), Cannabichromevarinic Acid (CBCVA), Cannabichromevarin (CBCV), Cannabidiolic Acid (CBDA), Cannabidiol (CBD), Δ6-Cannabidiol (Δ6-CBD), Cannabidiol monomethylether (CBDM), Cannabidiol-C4 (CBD-C4), Cannabidivarinic Acid (CBDVA), Cannabidivarin (CBDV), Cannabidiorcol (CBD-C1), Tetrahydrocannabinolic acid A (THCA-A), Tetrahydrocannabinolic acid B (THCA-B), Tetrahydrocannabinol (THC or Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), trans-Δ10-tetrahydrocannabinol (trans-Δ10-THC), cis-Δ10-tetrahydrocannabinol (cis-Δ10-THC), Tetrahydrocannabinolic acid C4 (THCA-C4), Tetrahydrocannabinol C4 (THC-C4), Tetrahydrocannabivarinic acid (THCVA), Tetrahydrocannabivarin (THCV), Δ8-Tetrahydrocannabivarin (Δ8-THCV), Δ9-Tetrahydrocannabivarin (Δ9-THCV), Tetrahydrocannabiorcolic acid (THCA-C1), Tetrahydrocannabiorcol (THC-C1), Δ7-cis-iso-tetrahydrocannabivarin, Δ8-tetrahydrocannabinolic acid (Δ8-THCA), Δ9-tetrahydrocannabinolic acid (Δ9-THCA), Cannabicyclolic acid (CBLA), Cannabicyclol (CBL), Cannabicyclovarin (CBLV), Cannabielsoic acid A (CBEA-A), Cannabielsoic acid B (CBEA-B), Cannabielsoin (CBE), Cannabinolic acid (CBNA), Cannabinol (CBN), Cannabinol methylether (CBNM), Cannabinol-C4 (CBN-C4), Cannabivarin (CBV), Cannabino-C2 (CBN-C2), Cannabiorcol (CBN-C1), Cannabinodiol (CBND), Cannabinodivarin (CBDV), Cannabitriol (CBT), 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC), 11 nor 9-carboxy-Δ9-tetrahydrocannabinol, Ethoxy-cannabitriolvarin (CBTVE), 10-Ethoxy-9-hydroxy-Δ6a-tetrahydrocannabinol, Cannabitriolvarin (CBTV), 8,9 Dihydroxy-Δ6a(10a)-tetrahydrocannabinol (8,9-Di-OH-CBT-C5), Dehydrocannabifuran (DCBF), Cannbifuran (CBF), Cannabichromanon (CBCN), Cannabicitran, 10-Oxo-Δ6a(10a)-tetrahydrocannabinol (OTHC), Δ9-cis-tetrahydrocannabinol (cis-THC), Cannabiripsol (CBR), 3,4,5,6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (OH-iso-HHCV), Trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC), Yangonin, Epigallocatechin gallate, Dodeca-2E, 4E, 8Z, 10Z-tetraenoic acid isobutylamide, hexahydrocannibinol, and Dodeca-2E,4E-dienoic acid isobutylamide.
- Within the context of this disclosure, where reference is made to a particular cannabinoid without specifying if it is acidic or neutral, each of the acid and/or decarboxylated forms are contemplated as both single molecules and mixtures.
- As used herein, the term “THC” refers to tetrahydrocannabinol. “THC” is used interchangeably herein with “Δ9-THC”.
- In select embodiments of the present disclosure, the first cannabinoid may comprise THC (Δ9-THC), THCA, Δ8-THC, trans-Δ10-THC, cis-Δ10-THC, THCV, THCVA, Δ8-THCV, Δ9-THCV, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, CBLVA CBT, CBTA, or cannabicitran.
- Structural formulae of cannabinoids of the present disclosure may include the following:
- In select embodiments of the present disclosure, the first cannabinoid may comprise CBD, CBDV, CBC, CBCV, CBG, CBGV, THC, THCV, or a regioisomer thereof. As used herein, the term “regioisomers” refers to compounds that differ only in the location of a particular functional group.
- In select embodiments of the present disclosure, the first cannabinoid is CBD.
- In select embodiments of the present disclosure, the first cannabinoid is Δ9-THC or Δ10-THC.
- As noted above, inducing a cannabinoid-rich solution into a supersaturated state is useful for promoting continuous cannabinoid crystallization. In select embodiments of the present disclosure, the inducing of the cannabinoid-rich solution to the supersaturated state may precede the mixing the cannabinoid-rich solution within the CSTR. Alternatively, the inducing of the cannabinoid-rich solution to the supersaturated state may be concurrent with the mixing the cannabinoid-rich solution within the CSTR.
- In select embodiments of the present disclosure, the supersaturation of a cannabinoid-rich solution may be induced by controlled temperature reduction. Hence, the methods of the present disclosure may further comprise cooling the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof either before or within the CSTR. For example, the cannabinoid-rich solution may comprise cannabidiol (CBD) with a CBD concentration of about 1 g/mL of solvent. In select embodiments of the present disclosure, the cannabinoid-rich solution may have a temperature of between about 0° C. and about 50° C. at an inlet to the CSTR.
- In select embodiments of the present disclosure, supersaturation of a cannabinoid-rich solution may be induced by evaporation. Hence, the methods of the present disclosure may further comprise evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR to reduce the volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof to between 80% and 20% of the initial volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof.
- In select embodiments of the present disclosure, the cannabinoid-rich solution may have a viscosity of between about 0.05 cP and about 250 cP at an inlet to the CSTR. For example, the cannabinoid-rich solution may comprise CBD and have a viscosity of about 1.0 cP.
- In select embodiments of the present disclosure, the cannabinoid-rich solution may have a fluid density of between about 0.2 g/mL and about 1,700 g/mL at an inlet to the CSTR. For example, the cannabinoid-rich solution may comprise CBD and have a fluid density of about 1.0 g/mL.
- In select embodiments of the present disclosure, the cannabinoid-rich solution may have a temperature of between about 0° C. and about 80° C. at an inlet to the CSTR. For example, the cannabinoid-rich solution may comprise CBD and have a temperature of about 50° C.
- In select embodiments of the present disclosure, the CSTR may be cylindrical in shape. The impeller may be positioned and oriented to align the axis of rotation of the impeller in a direction parallel to the cylinder axis of the CSTR. The impeller may be laterally offset from the center of the CSTR with an offset distance equal to one sixth the diameter of the CSTR. The impeller may have an impeller diameter equal to one third the diameter of the CSTR.
- In select embodiments of the present disclosure, mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with a Rushton turbine, a propeller, an anchor impeller, a gate-anchor impeller, a paddle impeller, a helical-screw impeller, a helical-ribbon impeller, or a combination thereof. For example, mixing the cannabinoid-rich solution with a propeller and/or a Rushton turbine may be advantageous when the viscosity of the cannabinoid-rich solution is below 10,000 centipoise.
- As will be appreciated by those skilled in the art who have benefited from the teachings of the present disclosure, turbulent mixing conditions within a CSTR give rise to turbulent eddies with a length scale that may be quantified by the Kolmogarov length scale λ as defined as by EQN. 3 and EQN. 4.
-
- Wherein:
- ν is the fluid kinematic viscosity (in m2/s);
- ε is the energy dissipation rate (kg/m·s);
- P is the input power (in kg·m2/s−3);
- ρ is the fluid density (in kg/m3); and
- Di is the diameter of the CSTR impeller (in m).
- In select embodiments of the present disclosure, mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with an energy dissipation rate to produce eddies with a Kolmogorov length scale larger than the size of the crystalline cannabinoid particles. As the energy dissipation rate increases (and therefore as the input power increases) for a CSTR, the Kolmogarov length scale of eddies within the CSTR decreases. Turbulent eddies smaller than the size of the crystalline cannabinoid particles may apply shear forces to the crystalline cannabinoid particles and thereby damage the crystalline cannabinoid particles.
- In select embodiments of the present disclosure, the tubular CSTR may comprise a baffle that is shaped, oriented, and positioned to redirect flow within the CSTR. For example, the baffle may be shaped, positioned, and oriented to redirect swirling flow within the CSTR to convert said swirling flow into turbulent flow. The baffle may be one of a plurality of baffles.
- As noted above, the severity of the turbulent mixing conditions required to induce crystal nucleation/growth from a particular cannabinoid-rich solution will vary depending on the particulars of the cannabinoid rich solution and the extent of supersaturation. However, for any particular solution/reactor combination, there is a critical Reynolds number that defines the minimum conditions required to ensure turbulent mixing. In select embodiments of the present disclosure, the critical Reynolds number may be greater than 500, 1,000, or 10,000. As will be appreciated by those skilled in the art who have benefitted from the teachings of the present disclosure, the diameter and/or shape of the impeller and the size and shape of the reactor may impact the critical Reynolds number, and these parameters can take any of a variety of forms provided that turbulent mixing conditions are achieved within the CSTR. Likewise, the diameter and/or the capacity of the CSTR is not limited to any particular value and can vary, provided that turbulent mixing conditions are achieved within the CSTR.
- In select embodiments of the present disclosure, the flow rate may be characterized as a linear flow rate, wherein the flow-rate is expressed in linear velocity units such as meters per second (m/s). Alternatively, the flow rate may be expressed as a volumetric flow rate. For example, flow rates may be expressed in volumetric velocity units such as liters per hour (L/h). Flow rates may also be expressed as a ratio of the total volume of the CSTR divided by the volumetric flow rate, for example the average residence time of fluid within the reactor (h). The flow rate may be characterized as the flow rate through an inlet to the CSTR. The flow rate may be characterized as the flow rate through an outlet to the CSTR.
- In select embodiments of the present disclosure, the cannabinoid-rich solution may comprise a solvent. The solvent may comprise pentane, hexane, heptane, methanol, ethanol, isopropanol, dimethyl sulfoxide, acetone, ethyl acetate, diethyl ether, tert-butyl methyl ether, water, acetic acid, anisole, 1-butanol, 2-butanol, butane, butyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, propane, propyl acetate, trimethylamine, or a combination thereof.
- In select embodiments, the methods of the present disclosure further comprise dispersing a plurality of seed crystals into the cannabinoid-rich solution concurrent with the mixing the cannabinoid-rich solution. In the context of the present disclosure, a seed crystal dispersion comprises at least one seed crystal dispersed in at least one solvent. A seed crystal is a crystal with a size smaller than the crystal size of the desired product. Addition of seed crystals may be advantageous as the presence of seed crystals obviates the need for nucleation during crystallization, and so long as the seed crystal size and size distribution remain constant the size and size distribution of the resulting crystalline cannabinoid particles will remain constant. Variations in the rate of nucleation contribute to variation in size distribution, therefore obviating the need for nucleation may increase the reliability of the crystallization.
- Crystalline cannabinoids produced by continuous crystallization can be modified by means of salt formation, co-crystallization, derivatization (e.g. esterification, etherification, isomerization, alkylation, arylation, oxidation, reduction, ring-opening/ring-closing reactions). Previously crystallized material can be further purified by recrystallization using CSTR to obtain enhanced cannabinoid purity. Recrystallization may also be conducted on modified crystal forms (e.g. carboxylate salts, co-crystals, synthetic derivatives) originally obtained by continuous crystallization.
- In select embodiments, the methods of the present disclosure further comprise flowing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution into an additional CSTR, mixing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution to form a plurality of larger crystalline cannabinoid particles within the additional CSTR, and discharging the plurality of larger crystalline cannabinoid particles and the cannabinoid-depleted solution from the additional CSTR in a continuous manner to provide a flow rate through the additional CSTR. Separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may include separating the larger crystalline cannabinoid particles from plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution. In select embodiments, the methods of the present disclosure further comprise flowing, mixing, and discharging through a plurality of additional CSTRs in a manner substantively similar to the method described above. Operating multiple CSTRs in series, as described above, may provide near-plug flow conditions since a plurality of CSTRs possess a narrower residence time distribution than a single CSTR with a capacity equal to the total capacity of the plurality of CSTRs.
- Embodiments of the present disclosure will now be described by reference to
FIG. 1 toFIG. 3 , which show representations of the physical structures and methods for continuously crystallizing cannabinoids according to the present disclosure. -
FIG. 1 shows a schematic diagram of anexemplary CSTR 100 which may be employed in executing a method in accordance with the present disclosure.CSTR 100 comprisesreaction vessel 110,inlet 112,outlet 114,additional inlet 116, a plurality ofbaffles 118,impeller 120,axle 122,motor 124,jacket 130,jacket inlet 132, andjacket outlet 134. -
Reactor vessel 110 comprises a reactor vessel wall to define a volume within which crystallization may occur.Reactor vessel 110 may comprise impermeable and generally chemically inert materials, for example glass or stainless steel.Reactor vessel 110 possesses a cylindrical shape and areactor vessel diameter 128.Impeller 120 is positioned and oriented to align the axis of rotation of the impeller with the cylinder axis ofreactor vessel 110. -
Reactor vessel 110 may be completely filled with fluid. Alternatively, reactor vessel may be partially filled with fluid, with the remaining volume filled with gas. The gas-filled volume may be referred to as head space, and the head space may be filled with inert gas, for example argon or nitrogen. The fluid withinreactor vessel 110 may completely immerseimpeller 120, where immersingimpeller 120 may be advantageous to ensure effective mixing of the fluid withinreactor vessel 110. -
Impeller 120,axle 122, andmotor 124 may be referred to collectively as a mixer.Impeller 120 is physically coupled toaxle 122.Axle 122 is physically coupled tomotor 124.Axle 122 may be physically coupledmotor 124 by gears, a pulley, a transmission, or by directly couplingaxle 122 to a drive shaft ofmotor 124. Directly physically couplingaxle 122 to a drive shaft ofmotor 124 may include welding, bolting, and/or adheringaxle 122 to a drive shaft ofmotor 124.Axle 122 passes through the wall ofreactor vessel 110.Axle 122 may pass through the wall ofreactor vessel 110 via a seal.Impeller 120 comprises a paddle impeller. - Power may be applied to
motor 124, causingmotor 124 to turnimpeller 120 viaaxle 122. The rate at which motor 124 turnsimpeller 120 comprises a mixingspeed N. Impeller 120 has animpeller diameter 126. Turningimpeller 120 causes the outermost tip ofimpeller 120 to turn with a velocity that depends on the mixing speed N andimpeller diameter 126. Fluid in contact withimpeller 120 whileimpeller 120 turns will flow, with the nature of said flow depending on the geometry ofreactor vessel 110, the mixing speed N, andimpeller diameter 126.Impeller diameter 126 may advantageously be about one third ofreactor vessel diameter 128 to maximize mixing efficiency. -
Inlet 112 comprises a channel betweenreactor vessel 110 and the exterior ofreactor vessel 110 through which fluids may pass.Inlet 112 comprises a tube passing through the wall ofreactor vessel 110. The exterior side ofinlet 112 may comprise a fitting to which a hose or a pipe may be attached. The reactor vessel side ofinlet 112 may comprise a nozzle to direct the flow of fluid throughinlet 112 intoreactor vessel 110 in a single direction, for example downwards to fall into a layer of fluid withinreactor vessel 112, or along the wall ofreactor vessel 110. Whileinlet 112 is depicted inFIG. 1 as being located at the top ofreactor vessel 110, those skilled in the art will appreciate thatinlet 112 may be relocated to a variety of suitable locations inreactor vessel 110 provided that fluids are able to flow intoreactor vessel 110 throughinlet 112. -
Outlet 114 comprises a channel betweenreactor vessel 110 and the exterior ofreactor vessel 110 through which fluids may pass.Outlet 114 comprises a tube passing through the wall ofreactor vessel 110. The exterior side ofoutlet 114 may comprise a fitting to which a hose or a pipe may be attached. Whileoutlet 114 is depicted inFIG. 1 as being located at the bottom ofreactor vessel 110, those skilled in the art will appreciate thatoutlet 114 may be relocated to a variety of suitable locations inreactor vessel 110 provided that fluids may be discharged fromreactor vessel 110 throughoutlet 114. - In the
reactor 100 depicted inFIG. 1 , each of the plurality ofbaffles 118 is physically coupled to the interior ofreactor vessel 110. Each of the plurality ofbaffles 118 is shaped, positioned, and oriented withinreactor vessel 110 to redirect the flow of fluid withinreactor vessel 110. For example, turningimpeller 120 may cause fluid to adjacent to the walls of reactor vessel 110 (and therefore furthest from impeller 120) to swirl (i.e. undergo laminar flow in a direction parallel to the walls of reactor vessel 110). Plurality ofbaffles 118 are positioned perpendicular to the direction of said flow, causing said laminar flow to be diverted away from the wall ofreactor vessel 110 and thereby cause said flow to become turbulent. -
Jacket 130 surroundsreactor vessel 110.Jacket 130 forms a space aroundreactor vessel 110 through which a thermal fluid may be circulated.Jacket 130 comprises thermalfluid inlet 132 through which thermal fluid may enterjacket 130.Jacket 130 comprises thermalfluid outlet 134 through which thermal fluid may exitjacket 130. Thermal fluid circulating throughjacket 130 may be thermally coupled toreactor vessel 110, thereby allowing heat transfer between a thermal fluid andreactor vessel 110.Reactor vessel 110 may be thermally coupled to fluids withinreactor vessel 110. In other words,jacket 130 may allow heating and/or cooling of a fluid withinreactor vessel 110. -
FIG. 2 shows a schematic diagram of twoexemplary CSTRs 100 linked in series. Fluid flow inFIG. 2 is depicted by a dashed line. Fluid may enter afirst CSTR 100 through afirst inlet 112. Fluid may then be mixed by a first mixer comprising afirst motor 124,first axle 122, andfirst impeller 120. Fluid may then exitfirst CSTR 100 viafirst outlet 114. Fluid may then enter asecond CSTR 100 through asecond inlet 112. Fluid may then be mixed by a second mixer comprising asecond motor 124,second axle 122, andsecond impeller 120. Fluid may then exitsecond CSTR 100 viasecond outlet 114.First outlet 114 may be fluidically coupled tosecond inlet 112 via a pipe, a hose, a pump, or the like. -
FIG. 3 shows a flow diagram for amethod 300 for continuously preparing crystalline cannabinoid particles.Method 300 comprises six steps: preparing a cannabinoid-rich solution that comprises a first cannabinoid (step 302); inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid (step 304); flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner (step 306); mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR (step 308); discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the CSTR (step 310); and separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution in a continuous manner (step 312). Instep 308, the turbulent mixing conditions are defined by a Reynolds number that is greater than a critical Reynolds number for the cannabinoid-rich solution and the CSTR. Throughout the description ofmethod 300, equivalent physical structures fromFIG. 1 andFIG. 2 are called out in brackets for illustrative purposes. - At
step 302, a first cannabinoid-rich solution that comprises a first cannabinoid is prepared. The cannabinoid-rich solution may comprise a cannabinoid extract, a cannabinoid resin, a cannabinoid distillate, a cannabinoid isolate, or a combination thereof. The first cannabinoid may be Δ9-tetrahydrocannabinolic acid, Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinolic acid, Δ8-tetrahydrocannabinol, cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabichromenic acid, cannabichromene, cannabinolic acid, cannabinol, Δ9-tetrahydrocannabivarinic acid, Δ9-tetrahydrocannabivarin, cannabigerivarin, cannabidivarin, cannabichromevarin, 11-hydroxy-Δ9-tetrahydrocannabinol, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, or a combination thereof. The cannabinoid-rich solution may comprise Δ9-tetrahydrocannabinolic acid, Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinolic acid, Δ8-tetrahydrocannabinol, cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabichromenic acid, cannabichromene, cannabinolic acid, cannabinol, Δ9-tetrahydrocannabivarinic acid, Δ9-tetrahydrocannabivarin, cannabigerivarin, cannabidivarin, cannabichromevarin, 11-hydroxy-Δ9-tetrahydrocannabinol, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, or a combination thereof. - The cannabinoid-rich solution may comprise a solvent. The solvent may comprise pentane, hexane, heptane, methanol, ethanol, isopropanol, dimethyl sulfoxide, acetone, ethyl acetate, diethyl ether, tert-butyl methyl ether, water, acetic acid, anisole, 1-butanol, 2-butanol, butane, butyl acetate, ethyl formate, formic acid, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methyl-1-propanol, 1-pentanol, 1-propanol, propane, propyl acetate, trimethylamine, or a combination thereof. The cannabinoid-rich solution may further comprise an excipient. In the context of
method 300, the cannabinoid-rich solution may comprise a solvent, or a mixture of solvents. A mixture of solvents may be advantageous to achieve a desired nucleation or crystal growth rate. The solvent may comprise a Class III solvent, where Class III solvents are advantageous for active pharmaceutical ingredient preparation due to their low toxicity. - At
step 304, the cannabinoid-rich solution is induced to a supersaturated state. As discussed above, a solvent is supersaturated when the concentration of solute in a given solution is above the solubility limit for said solution. The degree of supersaturation of a solution comprises the amount by which the concentration of the supersaturated solution exceeds the saturation concentration of said supersaturated solution. The degree of supersaturation may be expressed in absolute units (e.g. moles/liter or grams/liter) or in relative units (e.g. [solute concentration]/[saturation concentration]×100%). Supersaturating a cannabinoid solution may include causing a solution to possess a solute concentration above the solubility limit of the solvent. A person of ordinary skill in the art will appreciate that the solubility limit of a given cannabinoid solution depends on at least the temperature of the solution, the cannabinoid in question, the solvent in question, and the presence of any non-solvents. Non-exclusive methods by which a solution may be supersaturated include cooling, evaporation, and adding a non-solvent. - The saturation concentration of a cannabinoid in a solvent depends on the temperature of the solution, with a higher temperature typically yielding a higher saturation concentration. A saturated solution may be prepared by combining an excess amount a solid (i.e. undissolved) cannabinoid with a solvent at a temperature equal to the boiling point of the solid. A portion of the cannabinoid will dissolve in the solvent, with the excess being unable to dissolve due to saturation of the solvent with dissolved cannabinoid. The undissolved solid cannabinoid may then be separated from the cannabinoid solution to yield a saturated cannabinoid solution. Cooling of said saturated solution will decrease the solubility limit of the solvent, and since the amount of cannabinoid dissolved in the solution is now above the new solubility limit the solution becomes supersaturated by cooling.
- The saturation concentration of a cannabinoid in a solvent depends on the composition of the solvent. The solvent may comprise a mixture of solvents, where the mixture of solvents may comprise at least one cannabinoid solvent and at least one cannabinoid non-solvent. A cannabinoid solvent is a solvent that is able to dissolve at least twice the amount of the cannabinoid as the cannabinoid non-solvent. The cannabinoid may be dissolved in the cannabinoid solvent to saturate the cannabinoid solvent, then the cannabinoid solution may be mixed with the cannabinoid non-solvent to form the mixture of solvents. The presence of the non-solvent decreases the saturation concentration of the cannabinoid in the mixture of solvents. The mixture of solvents may therefore become supersaturated by decreasing the saturation concentration of the cannabinoid in the mixture of solvents below the actual concentration of the cannabinoid in the mixture.
- At
step 306, the cannabinoid-rich solution is flowed into a CSTR (100) in a continuous manner. The CSTR (100) may comprise a reaction vessel (110), an inlet (112) comprising an opening in the reaction vessel (110) through which the first cannabinoid solution flows, an outlet (114), an additional inlet (116), a baffle (118), a mixer comprising an impeller (120), an axle (122), and a motor (124), and a jacket (130) comprising a jacket inlet (132), and jacket outlet (134). The baffle (118) may be shaped, oriented, and/or positioned to redirect flow within the CSTR. The baffle (118) may be one of a plurality of baffles (118). The CSTR (100) may be cylindrical, and the impeller (120) may be positioned and oriented to align the axis of rotation of the impeller with the cylinder axis. - The cannabinoid-rich solution may have a viscosity of between about 0.05 and about 250 cP at an inlet (112) to the CSTR. The cannabinoid-rich solution may have a fluid density of between about 0.02 g/mL and about 1,700 g/mL at an inlet (112) to the CSTR. The cannabinoid-rich solution may have a temperature of between about 0° C. and about 80° C. at an inlet (112) to the CSTR.
- At
step 308, the cannabinoid-rich solution is mixed under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR (100). The cannabinoid-rich solution may mixed under turbulent mixing conditions with a mixer comprising an impeller (120), an axle (122), and a motor (124). The critical Reynolds number may be about equal to a Reynolds number above which a power number for the reactor is about constant. The critical Reynolds number may be greater than 10,000. Mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with an impeller (120), the impeller comprising a Rushton turbine, a propeller, an anchor impeller, a gate-anchor impeller, a paddle impeller, a helical screw impeller, a helical ribbon impeller, or any combination thereof. Mixing the cannabinoid-rich solution with the mixer may include turbulently mixing the cannabinoid-rich solution with the mixer wherein the impeller diameter (126) is about one third the diameter of the CSTR (128). - Mixing the cannabinoid-rich solution under turbulent mixing conditions may include mixing the cannabinoid-rich solution with an energy dissipation rate to produce eddies with a Kolmogorov length scale larger than the size of the crystalline cannabinoid particles.
- Crystallization may occur in a supersaturated solution via homogeneous nucleation. In homogeneous nucleation, dissolved individual solute molecules may encounter other dissolved individual solute molecules in a supersaturated solution and agglomerate together to form a small crystal nucleus. The crystal nucleus may then grow larger as additional solute molecules encounter and thereby attach to the surface of the crystal nucleus. However, while the interior bulk of a growing crystal is thermodynamically stable, the surface of the crystal is typically unstable, and thermodynamic instability provides an energy barrier to growth. For large crystal nuclei, the surface area to volume ratio is small which negates the energy barrier and causes crystal growth to be thermodynamically favorable, making large crystal nuclei stable. The rate of nucleation is the rate at which stable crystal nuclei form. A stable crystal nucleus may grow effectively indefinitely to form a large crystal. Small crystal nuclei have a high surface area to volume ratio which causes the energy barrier to growth to become significant, which makes dissolution of the small crystal nuclei thermodynamically favorable and causes small nuclei to be unstable. However, while dissolution of the small nuclei is favored, there exists a non-zero statistical probability that a small nucleus will grow to large enough to become stable and eventually grow to become a large crystal. The probability of an unstable crystal nucleus growing large enough to become stable, and thereby the rate of formation of stable crystal nuclei, increases as the degree of supersaturation of the solution increases. In other words, a higher degree of supersaturation of the solution increases the rate of homogeneous nucleation. Depending on the degree of supersaturation, the amount of time required to form at least one stable crystal nucleus may be on the order of second, hours, days, or months.
- Crystallization may occur in a supersaturated solution via heterogeneous nucleation. In heterogeneous nucleation, seed crystals are added to the supersaturated solution. Dissolved individual solute molecules may encounter and thereby attach to the surface of the seed crystal, causing the seed crystal to grow and eventually form a large crystal. A seed crystal may comprise the same material as the solute, or a different material from the solute. For example, seed crystals may be produced by milling the crystalline product of a previous crystallization to produce a large number of small seed crystals composed of the same material as the product to be crystallized. The presence of seed crystals in the supersaturated solution allows crystal growth to occur without the need for homogeneous nucleation. Homogeneous nucleation may require a relatively high degree of supersaturation.
- Inducing of the cannabinoid-rich solution to the supersaturated state may precedes the mixing the cannabinoid-rich solution. Inducing of the cannabinoid-rich solution to the supersaturated state may be concurrent with the mixing the cannabinoid-rich solution. In the context of the present disclosure, a narrow size distribution may be advantageous since a continuous separation method may be optimised to separate particles of a certain size and a narrow size distribution ensures the maximum number are of the optimal size. Crystalline cannabinoid particles with a size that closely matches the expected size will therefore also be closest to the optimal size of the separation method.
- At
step 310, the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution are discharged from the CSTR (100) in a continuous manner to provide a flow rate through the CSTR. The plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may be discharged via an outlet (114). - At
step 312, the crystalline cannabinoid particles are separated from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution in a continuous manner. Continuous separation may include centripetal separation, filter separation, and settling. As mentioned above, continuously separating crystalline cannabinoid particles is more efficient when the size and size distribution of the crystalline cannabinoid particles closely matches the size for which the separation method has been optimised. Separating the crystalline cannabinoid particles from the cannabinoid-depleted solution may include forming a mother liquor. - The
method 300 may further comprise reducing the volume of the mother liquor to form a concentrated mother liquor and a recycled solvent. Themethod 300 may further comprise mixing the concentrated mother liquor with a second cannabinoid solution to form a follow-on quantity of cannabinoid-rich solution. The follow-on quantity of cannabinoid-rich solution may comprise at least a portion of the first cannabinoid. Mixing the concentrated mother liquor with the second cannabinoid solution to form the follow-on quantity of cannabinoid-rich solution may increase the efficiency of the crystallization, since a portion of the dissolved cannabinoid that was not initially crystallized may crystallize when the concentrated mother liquor passes through the CSTR (100). - The
method 300 may further comprise dissolving at least a portion of the cannabinoid in the recycled solvent to form a third cannabinoid solution, dissolving the remainder of the cannabinoid in the solvent to form a fourth cannabinoid solution, and mixing the third and fourth cannabinoid solution to form the first cannabinoid solution. Using the recycled solvent to form the first cannabinoid solution decreases the cost of the crystallization since some of the solvent used for the crystallization may be re-used. - The
method 300 may further comprise cooling the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR. The cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR may be cooled by flowing a thermal fluid into a jacket (130) through a jacket inlet (132) and a jacket outlet (134). - The
method 300 may further comprise dispersing a plurality of seed crystals into the cannabinoid-rich solution concurrent with the mixing the cannabinoid-rich solution. The plurality of seed crystals may be dispersed into the cannabinoid-rich solution by flowing a dispersion comprising the plurality of seed crystals through an additional inlet (116). The plurality of seed crystals may be dispersed into the cannabinoid-rich solution by mixing a dispersion comprising the plurality of seed crystals with the cannabinoid-rich solution. - The
method 300 may further comprise evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof within the CSTR to reduce the volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof to between 80% and 20% of the initial volume of the cannabinoid-rich solution, the cannabinoid-depleted solution, or the combination thereof. Evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof may include evaporating the cannabinoid-rich solution, the cannabinoid-depleted solution, or a combination thereof under reduced pressure. - The
method 300 may further comprise flowing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution into an additional CSTR (100), mixing the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution to form a plurality of larger crystalline cannabinoid particles within the additional CSTR (100), and discharging the plurality of larger crystalline cannabinoid particles and the cannabinoid-depleted solution from the additional CSTR (100) in a continuous manner to provide a flow rate through the additional CSTR (100). Separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution may include separating the larger crystalline cannabinoid particles from plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution. - In the present disclosure, all terms referred to in singular form are meant to encompass plural forms of the same. Likewise, all terms referred to in plural form are meant to encompass singular forms of the same. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
- As used herein, the term “about” refers to an approximately +/−10% variation from a given value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
- It should be understood that the compositions and methods are described in terms of “comprising,” “containing,” or “including” various components or steps, the compositions and methods can also “consist essentially of or “consist of the various components and steps. Moreover, the indefinite articles “a” or “an,” as used in the claims, are defined herein to mean one or more than one of the element that it introduces.
- For the sake of brevity, only certain ranges are explicitly disclosed herein. However, ranges from any lower limit may be combined with any upper limit to recite a range not explicitly recited, as well as, ranges from any lower limit may be combined with any other lower limit to recite a range not explicitly recited, in the same way, ranges from any upper limit may be combined with any other upper limit to recite a range not explicitly recited. Additionally, whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range are specifically disclosed. In particular, every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values even if not explicitly recited. Thus, every point or individual value may serve as its own lower or upper limit combined with any other point or individual value or any other lower or upper limit, to recite a range not explicitly recited.
- Therefore, the present disclosure is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present disclosure may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Although individual embodiments are dis-cussed, the disclosure covers all combinations of all those embodiments. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present disclosure. If there is any conflict in the usages of a word or term in this specification and one or more patent(s) or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted.
- Many obvious variations of the embodiments set out herein will suggest themselves to those skilled in the art in light of the present disclosure. Such obvious variations are within the full intended scope of the appended claims.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/628,853 US11925907B2 (en) | 2019-07-22 | 2020-07-21 | Continuous crystallization of cannabinoids in a stirred-tank reactor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962877071P | 2019-07-22 | 2019-07-22 | |
US17/628,853 US11925907B2 (en) | 2019-07-22 | 2020-07-21 | Continuous crystallization of cannabinoids in a stirred-tank reactor |
PCT/CA2020/051005 WO2021012044A1 (en) | 2019-07-22 | 2020-07-21 | Continuous crystallization of cannabinoids in a stirred-tank reactor |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220249976A1 true US20220249976A1 (en) | 2022-08-11 |
US11925907B2 US11925907B2 (en) | 2024-03-12 |
Family
ID=74192767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/628,853 Active 2041-03-07 US11925907B2 (en) | 2019-07-22 | 2020-07-21 | Continuous crystallization of cannabinoids in a stirred-tank reactor |
Country Status (3)
Country | Link |
---|---|
US (1) | US11925907B2 (en) |
CA (1) | CA3148236A1 (en) |
WO (1) | WO2021012044A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022192793A1 (en) * | 2021-03-12 | 2022-09-15 | Treehouse Biosciences, Inc. | Solvent limited isolation of crystalline cannabinoids |
CN113274758A (en) * | 2021-06-24 | 2021-08-20 | 温州市金榜轻工机械有限公司 | Crystallizing tank for crystallizing cannabidiol in industrial hemp |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10189762B1 (en) * | 2017-07-07 | 2019-01-29 | Orochem Technologies, Inc. | Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377218A (en) | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
US7244307B2 (en) | 2002-05-31 | 2007-07-17 | Accentus Plc | Production of crystalline materials by using high intensity ultrasound |
DE10243837A1 (en) | 2002-09-13 | 2004-03-25 | Dr. Hielscher Gmbh | Process for continuously processing flowable compositions in a flow cell comprises indirectly sonicating the composition in the flow cell via a liquid placed under elevated pressure |
GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
GB2393182B (en) | 2002-09-23 | 2007-03-14 | Gw Pharma Ltd | Method of preparing cannabidiol from plant material |
SI1560819T1 (en) | 2002-11-12 | 2009-06-30 | Mallinckrodt Inc | Cannabinoid crystalline derivatives and process of cannabinoid purification |
NZ567029A (en) | 2005-09-29 | 2011-09-30 | Amr Technology Inc | Process for production of delta-9- tetrahydrocannabinol |
GB0523707D0 (en) | 2005-11-22 | 2005-12-28 | Nitech Solutions Ltd | Improved apparatus and method for temperature controlled processes |
GB0705159D0 (en) | 2007-03-19 | 2007-04-25 | Prosonix Ltd | Process for making crystals |
US20120315308A1 (en) | 2010-02-24 | 2012-12-13 | Travers William A | Methods and devices for controlling particle size and particle size distribution |
AU2011308865B2 (en) | 2010-09-29 | 2017-01-05 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
EP2744489A4 (en) | 2011-08-15 | 2015-03-18 | Abbott Lab | Process for manufacturing hmb and salts thereof |
NL1039053C2 (en) | 2011-09-19 | 2013-03-21 | Stichting Wetsus Ct Excellence Sustainable Water Technology | Device and method for a bioreactor, catalysis reactor or crystallizer without internals. |
CA2866787C (en) | 2011-09-29 | 2021-05-18 | Thc Pharm Gmbh The Health Concept | Cannabinoid carboxylic acids, salts of cannabinoid carboxylic acids, and the production and uses of same |
GB201121401D0 (en) | 2011-12-13 | 2012-01-25 | Univ Heriot Watt | Device for inducing nucleation |
US20150165340A1 (en) | 2012-09-03 | 2015-06-18 | Laminar Co., Ltd. | Purification System Comprising Continuous Reactor and Purification Method Using Continuous Reactor |
SG11201501712SA (en) | 2012-10-08 | 2015-05-28 | Exxonmobil Upstream Res Co | Separating carbon dioxide from natural gas liquids |
EP3057694B1 (en) | 2013-10-14 | 2019-05-15 | Universidade Do Porto | Apparatus for mixing based on oscillatory flow reactors provided with smooth periodic constrictions |
US9333229B2 (en) | 2013-10-16 | 2016-05-10 | William Bjorncrantz | Winterized crude cannabis extracts and methods of preparation and use |
FI20146163A (en) | 2014-12-30 | 2016-07-01 | Lappeenrannan Teknillinen Yliopisto | METHOD AND DEVICE FOR CONTINUOUS CRYSTALIZATION AND THEIR USE |
US9765000B2 (en) | 2015-01-22 | 2017-09-19 | Phytoplant Research S.L. | Methods of purifying cannabinoids, compositions and kits thereof |
US10207198B2 (en) | 2015-01-22 | 2019-02-19 | Phytoplant Research S.L. | Methods of purifying cannabinoids using liquid:liquid chromatography |
US9469548B2 (en) | 2015-02-20 | 2016-10-18 | Hydro Dynamics, Inc. | Continuous hydrodynamic cavitation crystallization |
ES2759568T3 (en) | 2015-03-23 | 2020-05-11 | Echo Pharmaceuticals Bv | Industrial hemp cannabidiol isolate and its use in pharmaceutical and / or cosmetic preparations |
US20170008870A1 (en) * | 2015-07-06 | 2017-01-12 | Clare J. Dibble | Methods for Obtaining Purified Cannabis Extracts and THCA Crystals |
HUE049895T2 (en) | 2015-12-21 | 2020-11-30 | Janssen Pharmaceutica Nv | Crystallization procedure for obtaining canagliflozin hemihydrate crystals |
US10399920B2 (en) | 2016-06-01 | 2019-09-03 | S&B Pharma, Inc. | Crystalline form of cannabidiol |
US10053407B2 (en) | 2016-06-01 | 2018-08-21 | S&B Pharma, Inc. | Crystalline cannabidivarin |
CA3123122A1 (en) | 2016-07-29 | 2018-02-01 | Pax Labs, Inc. | Methods and apparatuses for concentrate vaporization |
CN106278828A (en) | 2016-08-16 | 2017-01-04 | 云南汉素生物科技有限公司 | A kind of method extracting cannabidiol from industrial hemp floral leaf |
EP3558278B1 (en) | 2016-12-22 | 2021-07-14 | NordicCan A/S | Liquid cannabinoid composition |
EP3589129A4 (en) | 2017-03-01 | 2020-11-25 | Canopy Growth Corporation | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
IL271521B1 (en) | 2017-06-28 | 2024-02-01 | Altria Client Services Llc | Vaporizing devices and methods for delivering a compound using the same |
IT201700085508A1 (en) | 2017-07-26 | 2019-01-26 | Inalco S R L | METHOD FOR THE PRODUCTION OF CANNABINOIDS FROM VARIETY OF INDUSTRIAL HEMP |
US20190134121A1 (en) | 2017-08-08 | 2019-05-09 | Steven Bermudez | Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process |
WO2019056129A2 (en) | 2017-09-25 | 2019-03-28 | Canopy Health Innovations | Methods of personalizing compositions affecting insomnia |
US20200286597A1 (en) | 2017-10-04 | 2020-09-10 | Cannibite Bvba | System for Detecting an Intraoral Disease and Determining a Personalized Treatment Scheme and Method of Doing Same |
CN207384904U (en) | 2017-10-26 | 2018-05-22 | 云南汉素生物科技有限公司 | A kind of integrated system that cannabidiol is extracted from industrial hemp |
CN207591325U (en) | 2017-10-26 | 2018-07-10 | 云南汉素生物科技有限公司 | A kind of industrial hemp extraction cannabidiol isolates and purifies device |
CN108083989B (en) | 2018-01-10 | 2021-04-16 | 烟台汉麻生物技术有限公司 | Preparation method of high-purity cannabidiol |
CN108314608B (en) | 2018-02-05 | 2020-11-03 | 昆明医科大学第一附属医院 | Extraction and separation method of cannabidiol |
CN208292897U (en) | 2018-03-09 | 2018-12-28 | 陈天睿 | Totally-enclosed CBD automatically extracts production line |
CN109053388A (en) | 2018-08-20 | 2018-12-21 | 上海昶健生物科技有限公司 | A method of extracting cannabidiol |
CA3024431C (en) | 2018-11-15 | 2021-03-30 | Hexo Operations Inc. | Cannabis vape oil, method of use and of making same |
-
2020
- 2020-07-21 US US17/628,853 patent/US11925907B2/en active Active
- 2020-07-21 WO PCT/CA2020/051005 patent/WO2021012044A1/en active Application Filing
- 2020-07-21 CA CA3148236A patent/CA3148236A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10189762B1 (en) * | 2017-07-07 | 2019-01-29 | Orochem Technologies, Inc. | Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves |
US10843991B2 (en) * | 2017-07-07 | 2020-11-24 | Orochem Technologies Inc. | Process for separating a constituent/cannabinoid using a chromatographic resin |
Also Published As
Publication number | Publication date |
---|---|
US11925907B2 (en) | 2024-03-12 |
WO2021012044A1 (en) | 2021-01-28 |
CA3148236A1 (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11925907B2 (en) | Continuous crystallization of cannabinoids in a stirred-tank reactor | |
McGinty et al. | Nucleation and crystal growth in continuous crystallization | |
Eder et al. | Seed loading effects on the mean crystal size of acetylsalicylic acid in a continuous‐flow crystallization device | |
Kakran et al. | Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods | |
Brown et al. | Characterization and modelling of antisolvent crystallization of salicylic acid in a continuous oscillatory baffled crystallizer | |
DE112010001099B4 (en) | Multi-stage countercurrent rotary bed reactive distillation apparatus and their use | |
US20060118034A1 (en) | Hydrodynamic cavitation crystallization device and process | |
CN108939599A (en) | A kind of self-loopa crystallizer and multistage continuous crystallisation process | |
Lu et al. | Crystallization of an active pharmaceutical ingredient that oils out | |
US20080194868A1 (en) | Hydrodynamic cavitation crystallization device and process | |
CN102728094B (en) | Crystallization apparatus | |
US20220249430A1 (en) | Continuous crystallization of cannabinoids in a tubular flow reactor | |
Higami et al. | Simultaneous synchrotron radiation X-ray diffraction-DSC analysis of melting and crystallization behavior of trilauroylglycerol in nanoparticles of oil-in-water emulsion | |
US8216363B2 (en) | Continuous antisolvent crystallization process and system using plug flow reactors | |
EP1407805B1 (en) | Ring crystallizer method and apparatus | |
EP2471585A1 (en) | Apparatus and method for separating solid particles from a slurry | |
CN105859730A (en) | Method for preparing granular smooth epsilon-HNIW crystal through counter solvent dilution method | |
DE19851253A1 (en) | Bisphenol A is recovered from a stream containing phenol, water and acetone | |
EP1603652B1 (en) | Hydrodynamic cavitation crystallization process | |
Yuan et al. | Ultrasound‐assisted slug‐flow tubular crystallization for preparation of fine ibuprofen crystals | |
ES2575665T3 (en) | Apparatus for replacing a dispersion medium | |
JPH06239780A (en) | Method for hydration of cyclic olefin | |
KR20170128462A (en) | Bubble column reactor-based crackers and methods of using the same | |
JP5162960B2 (en) | Dispersion medium replacement method for isophthalic acid raw slurry | |
DE102009045767A1 (en) | Method for commissioning process for purified separation of acrylic acid crystals from suspension of its crystals in mother liquor with device having hydraulic washing column that has process chamber limited by a cylindrical lateral wall |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: CANOPY GROWTH CORPORATION, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ADAIR, CHRISTOPHER;GEILING, BEN;SIGNING DATES FROM 20200921 TO 20200930;REEL/FRAME:058723/0560 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, DELAWARE Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS;ASSIGNOR:CANOPY GROWTH CORPORATION;REEL/FRAME:065239/0156 Effective date: 20231003 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |